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The chemical diversity and biomedicinal potential of three South African actinomycetes, 
Streptomyces speibonae PK-BlueT, Streptomyces africanus CPJVR-HT and Streptomyces 
pharetrae CZA14T, was investigated. The primary aim was the isolation and structure 
elucidation of anti-tubercular natural products (NPs), including the re-isolation of the 
compound named PK-B, reported to be produced by S. speibonae PK-BlueT. 
Efforts were made to re-isolate the compound named PK-B. However, the results could not 
be replicated and focus was shifted to the bioassay-guided isolation of antimycobaterial 
compounds from the three actinobacteria. Culture conditions were optimised for 
antimycobacterial activity of S. speibonae PK-BlueT extracts by testing against the MTB 
analogue Mycobacterium aurum A+ (a non-pathogenic, fast-growing mycobacterium that has 
a similar antibiotic susceptibility to Mycobacterium tuberculosis). Bioactive crude extracts 
were prioritised for liquid-liquid partitioning and dereplication by LR LC-MS, followed by 
prefractionation and purification using a combination of HPLC and benchtop column 
chromatography. Structure elucidation of isolated compounds was achieved using NMR, LC-
MS and GC-MS data. Bioassays against M. aurum A+ were implemented at every stage of the 
isolation process to make sure that the isolated compounds had antimycobacterial activity. 
This strategy led to the isolation of four known compounds, the alkaloid N-phenylpyridin-2-
aminium (3.1), a 1:1 mixture of the long-chain fatty acids (LCFAs) n-hexadecanoic acid (3.2) 
and 14-methylpentadecanoic acid (3.3), and the isoflavone 7-hydroxy-3-(4-hydroxyphenyl)-
4H-chromen-4-one (3.4), from S. speibonae PK-BlueT cultures. Of the four isolated 
compounds, only 3.1 has not previously been reported from a natural source. The approach 
of using M. aurum A+ in searching for anti-tubercular compounds was vindicated as 3.1, the 
mixture of 3.2 and 3.3, and 3.4, in addition to inhibiting the growth of M. aurum A+, exhibited 
activity against M. tuberculosis H37RvT with MIC90 values of 135 μM, 26 μM and 195 μM, 
respectively. 
Additionally, the effect of different growth media on the chemical diversity of S. speibonae 
PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T extracts was demonstrated by 
bioassay where the extracts were screened against a panel of test organisms.  HR LC-MS 
dereplication was used to identify a list of 11 suggested molecular formulae of potentially 
iv 
novel, bioactive NPs in liquid-liquid partitioned extracts of theses three filamentous 
actinobacteria. Unfortunately, these compounds could not be investigated further due to low 
biomass and time limitations. 
v 
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Tuberculosis (TB) is the second most lethal infectious disease globally, behind Human 
Immunodeficiency Virus infection and the associated acquired immune deficiency syndrome 
(HIV/AIDS),1 and is responsible for the deaths of approximately 1.3 million people yearly.2 This 
mortality rate is remarkably high given that the disease has been extensively researched and 
therapeutics are available.3 Mycobacterium tuberculosis (MTB) was identified as the causative 
agent of TB as far back as 18824 but, despite efforts to eradicate the disease, there has been 
no decline in disease incidence.5 Instead, recent years have seen greater numbers of TB cases 
than ever before, with an estimated 1.7 billion people infected with latent TB globally and 
10.4 million new cases in 2016,6 which is a result of the pathogenesis and biology of the 
bacterium.5 While this pathophysiology is understood, it does have inherent complications 
for drug treatment, even in uncomplicated cases.3 In such cases, activation of the immune 
system leads to the formation of granulomas, multicellular structures that surround and 
contain the pathogen, which slows disease progression but also decreases drug 
susceptibility.3 This leads to a latent TB infection in most cases, which in 10% of cases results 
in post-primary reactivation and active and chronic disease.3  
Another reason for the high rate of TB is treatment cost and duration, which has led to 
increased TB prevalence in the developing world where public health systems are especially 
overburdened.7 The standard chemotherapeutic regimen for uncomplicated TB cases 
requires a two-month course of combination therapy of the four drugs isoniazid (1.1), 
rifampicin (1.2), pyrazinamide (1.3) and ethambutol (1.4) and a further four-month 
combination treatment with isoniazid and rifampicin.8 Failure to implement this regimen 
successfully has led to drug resistant forms of MTB and this, along with other factors such as 
coinfection with HIV and/or the patient suffering from diabetes, plays a significant role in the 
high death rates associated with TB.9 This has led the World Health Organisation (WHO) to 
list multi-drug resistant TB (MDR-TB) as a global threat.10  
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MDR-TB and extensively drug resistant TB (XDR-TB), which accounts for 5.4% of MDR-TB 
cases, are becoming increasingly common with a worldwide diagnosis rate of almost half a 
million infections per year and an estimated mortality rate of 33%.2 This high mortality rate is 
usually attributed to failure of diagnosis or the lack of appropriate treatment.2 The treatment 
regime is longer for MDR-TB cases than for uncomplicated TB cases (at least 8 months), and 
includes combination treatment with second-line drugs such as capreomycin (1.5), 
cycloserine (1.6), ethionamide (1.7), kanamycin (1.8) and para-amino salicylate (1.9).11 
Treatment with these second-line drugs is more expensive than regular treatment and is also 
less effective and more toxic to the patient, which contributes to the spread of the disease.12 
This is especially evident in South Africa where the number of MDR-TB cases is conservatively 
estimated at 13 000 per year and where XDR-TB which, by definition, has resistance to 
isoniazid and rifampicin and at least three of the second-line drugs,13 is a growing epidemic.14 
Additionally, the HIV epidemic has resulted in large numbers of people with increased 
susceptibility to TB and this has resulted in especially high mortality rates among HIV and TB 
coinfections.15 The increased cost and duration of treatment of drug resistant TB and the fact 
that diagnosis of TB is hampered by HIV coinfection mean that control of both diseases is 
diminished and highlights the need for new and improved drugs for the treatment of TB.14  
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There has been significant investment to this end, but the approval of the anti-MDR TB agent 
bedaquiline (1.10) in 2012 was the first such advance in thirty years, and this drug requires 
combination therapy with other TB drugs.16 The problem of complicated drug regimens 
therefore remains, and consequently the need for the development of new TB drugs that can 
shorten treatment duration, target drug resistant TB, simplify the pill burden and dose 
frequency and be co-administered with HIV medications.17 Discovery of new agents with the 
required chemical properties for effective TB treatment requires the discovery of novel drugs, 
a potential source of which are natural products (NPs) which have been and remain an 
excellent source of novel drugs.18 
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1.2 Natural Products 
 
NPs are compounds that are naturally produced by living organisms, although the term 
usually refers more specifically to naturally occurring secondary metabolites.19 Secondary 
metabolites are differentiated from primary metabolites as compounds that are not essential 
to the growth and development of the producing organism, i.e. primary metabolites are 
required for growth.19 Secondary metabolites are instead believed to confer a survival 
advantage to the producing organism as they are responsible for activities such as repelling 
competitors or predators and they can be classified into five major compound classes: 
terpenoids and steroids, alkaloids, fatty acids and polyketides, non-ribosomal peptides and 
enzyme cofactors.19 Secondary metabolites have had a variety of uses for human-kind and 
have been of great importance in both traditional and modern medicine, as will be discussed 
further.20  
 
1.2.1 A Brief History of Medicinal Natural Products 
 
For thousands of years, NPs have been at the centre of traditional medicine systems.20 The 
first written records of NPs in medicine are detailed in cuneiform on Mesopotamian clay 
tablets from circa 2600 BCE.20 These tablets indicate the use of oils from various plants 
including Cedrus species (cedar) and Cupressus semervirens (cypress), as well as substances 
from Glycyrrhiza glabra (licorice) and Papaver somniferum (poppy juice), all of which are still 
used today as remedies for a wide array of illnesses.20 Other instances where NPs are 
documented to be used in sophisticated traditional medicine systems are the Ebers Papyrus 
from Egypt  (1500 BCE), which detailed 700 primarily plant-derived drugs, the Chinese Materia 
Medica (52 prescriptions) that was recorded from about 1100 BCE and the Indian Ayervedic 
from about 1000 BCE.20 The ancient Greeks were also influential in the development of herbs 
as drugs, as recorded in Theophastus’ History of Plants (ca 300 BCE), a compendium on the 
medicinal properties of herbs.20  
The first privately owned drug stores were introduced in Arabia in the eighth century where 
Arab resources, Chinese and Indian herbs and Western knowledge was assembled and 
6 
recorded.20 The WHO estimates that plant-based traditional medicine systems such as these 
continue to provide primary health care for 80% of the global population, mostly in less 
developed countries, as well as playing an important role in developed countries.21 
There have also been great advances in NP drug discovery in modern history. The antimalarial 
drug quinine (1.11) was isolated from the then-known antimalarial bark of Cinchona species 
by French pharmacists in 1820.20 This drug was also used in the synthesis of the antimalarial 
drugs chloroquine (1.12) and mefloquine (1.13).20 As resistance to 1.11 – 1.13 developed, NPs 
were again a source of antimalarial drugs in the form of artemisinin (1.14), which was isolated 
from Artemisia annua, a plant used in traditional Chinese medicine to treat fevers, and its 
derivatives artemether (1.15) and arteether (1.16).20  
Another significant NP discovery in recent history is the 1816 isolation of morphine (1.17) 
from Papaver somniferum, which was used in ancient Mesopotamia, as mentioned above.20 






1.2.2 Natural Products and drug discovery 
 
Penicillin G (1.18) was discovered in 1929 and has been used therapeutically since 1942.22 The 
medical application of 1.18 has led to what is often termed the “golden age of antibiotics”.22 
For decades thereafter, most notably the 1950s and ‘60s, the pharmaceutical industry 
benefited from consistent drug approvals, including many of the antibiotics and 
chemotherapies still in use today, and significant drug approval rate increases.23 The vast 
majority of these antibiotics were NPs.24  
However, challenges inherent in NP drug discovery led to a shift away from NP chemistry from 
the 1980s till the late 2000s.25 NP chemistry is an expensive undertaking, which is why this 
research was led by big pharma and other large organizations.25 Other difficulties include the 
length of time required to identify and characterise the active components in natural extracts, 
the risk of re-isolating known compounds and further complications in obtaining sufficient 
quantities of NP leads.25,26 This supply issue is due to the NP leads most often being minor 
components of natural extracts and the need for large-scale acquisition of natural samples 
can hinder progress to pre-clinical development.25  
Due to the difficulties in NP drug discovery an alternative method was explored.25 The 
advances made in computing in the 1980s allowed the development of compound libraries 
for high-throughput screening (HTS).25 Generation of random compound libraries through 
combinatorial chemistry (the mass synthesis of chemicals from known building blocks)25 
provided large numbers of compounds that could be rapidly screened for activity,  and these 
methods were adopted by pharmaceutical companies at the expense of NP research.22,23 
However, the anticipated success in drug discovery has not been forthcoming and only three 
de novo combinatorial compounds, sorafenib (1.19),27 ataluren (1.20)28 and vemurafenib 
(1.21),29 have been approved globally since 1981.18  
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Between 1981 and 2014, despite the emphasis on HTS and combinatorial chemistry, 26% of 
total global drug approvals (Figure 1.1) and 33% of small molecule drug approvals were 
sourced from unaltered NPs, natural botanical compounds or NP derivatives.18 Of these 
approved compounds, 24 NP drugs were investigated by Ganesan,30 consisting mainly of 
polyketides, peptides and terpenoids and included bestatin (1.22), thienamycin (1.23), taxol 
(1.24) and rapamycin (1.25). This study examined the structural properties of these drugs in 
terms of Lipinski’s Rule of Five (RO5).30,31 Lipinski’s RO5 are a set of guidelines used in 
medicinal chemistry drug design that allow physico-chemical predictions to be made based 
on molecular structure.22,31 These predictions can be used to guide the design of compounds 
with good oral bioavailability and the desired ADMET (absorption, distribution, metabolism, 
excretion and toxicity) molecular properties.22,31 Interestingly, this study demonstrated 
Lipinski’s fifth rule, which states that the first four rules, which outline structural parameters 
for drugs with effective oral bioavailability, do not apply to NPs.18,30  NP drugs and drug leads 
therefore fall outside the parameters considered to be important by medicinal chemists while 




Figure 1.1: Source of all drugs approved globally from 1981 – 2014, adapted from Newman 




NPs occupy a larger area of “chemical space” (i.e. have greater structural diversity) than 
synthetic compounds and hence exhibit greater chemical diversity.32 This is a result of the 
differences in the methods employed in the formation of compounds.30 Biosynthesis makes 
use of a very limited number of starting materials compared to those available to synthetic 
chemists, but follows far more complex pathways to achieve greater structural diversity, 
creating molecules richer in stereochemical features, such as chiral centres.30 Furthermore, 
while NPs are not specifically active against human drug targets, they have coevolved over 
time within their own natural systems to interact with their own host proteins, many of which 
are structurally similar to those found in human systems.25,33 NPs are therefore a potential 
source for novel and bioactive compounds and novel scaffolds that can be readily developed 
in conjunction with synthetic chemistry for drug discovery.30 This fact has seen the re-
emergence of NP discovery in drug research in recent years.34  
 
1.2.3 Microbes as a source of Natural Products 
   
Microbes have been shown to be the most promising source for the discovery of novel NP 
skeletons and microbial NPs have been highly significant in the production of antibiotic 
drugs.18 The first major discovery was in 1929 with Alexander Fleming’s identification of 1.18 
from the fungus Penicillium notatum, which went on to be used as an immensely important 
antibiotic from the 1940s.24 As described above, this discovery was the catalyst for the 
“golden age of antibiotics” in the 1950s and ’60s, during which time the majority of antibiotic 
discovery is attributed to actinobacterial sources.35 In fact, it was during this time that nearly 
all the important classes of antibacterial antibiotics (tetracyclines, cephalosporins, 
aminoglycosides, macrolides) were discovered and the actinomycete genus Streptomyces 
accounted for 70 - 80% of all isolated compounds.35 Actinobacteria are Gram positive bacteria 
that have a high guanine-cytosine (G+C) content in their deoxyribonucleic acid (DNA).36 The 
filamentous actinobacteria are often called actinomycetes.36 
The discovery rate of new antibiotics was less prolific in the following two decades.35 Of the 
newly discovered antibiotics, 65 - 70% were obtained from actinomycetes, making them the 
major source, but many new chemical entities (NCEs) were found to be analogues of known 
compounds.35 At the same time, emergence of MDR pathogens was complicating 
11 
chemotherapeutic treatments.35 In an effort to increase the discovery rate of NCEs, a wider 
range of microbes was investigated for bioactive NP production.35 This broadened microbial 
investigation resulted in an increase in the discovery of “rare actinomycete” products, 
approximately 30% of new bioactive microbial NPs, but the rate of antibiotic drug discovery 
was slow.35 The subsequent shift in focus towards HTS and combinatorial chemistry instead 
of NP chemistry, while still yielding high numbers of new metabolites, was also not effective 
in increasing the rate of antibiotic discovery.35 Three decades after the advent of HTS and 
combinatorial chemistry, microbial NPs from actinomycetes continue to be responsible for 
the majority of therapeutic antibiotics.35 
Actinomycetes, especially soil streptomycetes, are prolific producers of antibiotics37 and are 
responsible for many well-known antibiotics, such as the bactericidal aminoglycoside 
streptomycin (1.26), which was the first anti-TB drug, from Streptomyces griseus.38 Other 
important drugs from streptomycetes include the antibacterial polyketide tetracycline (1.27) 
from Streptomyces aureofaciens,39 the lipopeptide anti-infectant daptomycin (1.28) from 
Streptomyces roseosporus40 and the antimycobacterial agent analogues of griselimycin (1.29 
– 1.31).34 Despite producing such a vast array of antibiotics, actinomycetes are still considered 
a relatively untapped source thereof.41 Even though 45% of bioactive microbial NPs are 
reported to be sourced from actinomycetes, there is undoubtedly still huge potential for 




1.2.4 South African actinomycetes and NP research 
 
A search of the literature available through the Scifinder database revealed that South African 
actinomycetes have not been extensively investigated for bioactive compounds.42 Using the 
Scifinder database and the terms “South Africa” or “South African” in combination with 
“bacteria”, “actinobacteria” or “actinomycetes” revealed that few NPs have been reported to 
be isolated from South African actinomycetes.42 Two antibiotics were found to be produced 
by actinomycetes isolated in South Africa, although this work was conducted abroad.43,44 The 
first was the polyene macrolide antifungal, pimaricin (1.32), which is produced by 
Streptomyces natalensis and is used as a preservative in yoghurt.43 The second was the broad-
spectrum antibiotic against Gram positive bacteria, platensimycin (1.33), which is produced 
by Streptomyces platensis.44 Previous efforts have been made, however, to investigate the 
microbial biodiversity in South Africa. In a Ph.D. study by Bronwyn Kirby at the University of 
13 
Cape Town (UCT), 30 actinomycete strains belonging to six different genera were selected for 
analysis: 13 Streptomyces, eight Micromonospora, two Kribbella, four Kineococcus, two 
Gordonia and one Nocardia.45 These strains were subjected to phylogenetic analysis, 
phenotypic characterisation and chemotaxonomic classification and then tested for 
antimycobacterial activity against M. aurum A+, Mycobacterium smegmatis LR222 and 
Mycobacterium bovis BCG (Tokyo) (Table 1.1).45  
 
Of the 30 isolates, 24 inhibited the growth of M. aurum A+ through the production of 
antimycobacterial compounds.45 As M. aurum A+ is a non-pathogenic strain with a similar 
antibiotic susceptibility profile to MTB, this data can be useful in identifying new strains 
producing potentially new anti-tubercular compounds.46 Other South African actinomycetes 
that have been identified as producers of antimycobacterial compounds are Streptomyces 











Table 1.1: Antimycobacterial activity of a collection of South African actinomycete strains.45 








sediment Berg1C + + + 
Berg2S + + + 
Berg4Y + + - 
Muiz4Y + + + 
NX03U2 + + + 
Riet1C - + + 
Zand2Y + - - 
Zand4Y - + - 
Zand8Y + + + 
Zand9Y + + + 
soil Hel32 + + + 
PHelU5 + - - 
ShaleUP - + + 
Micromonospora 
sediment CGM31 - - - 
MuizA5S - - - 
PLU1 - - - 
VleiA3C - - - 
plant DG41 - - - 
PBPE - - - 
TVU1 + - - 
Kribbella 
soil HMC25 - - - 
Q41 - - - 
Gordonia plant AC41 + - - 
Nocardia soil M25 - - - 
 + = antimycobacterial activity; - = no antimycobacterial activity 
 
1.3  An overview of bioassay-guided isolation of NPs 
 
Several approaches can be employed for the isolation of NPs, where the strategy chosen is 
based on the aim of the research. Examples include bioassay-, chemistry- and metabolomics 
guided isolation, focusing on bioactive NPs, NPs with novel chemical structures or NPs present 
in an organism at a specific time and under specific influences, respectively.49,50 In this thesis, 
bioassay-guided isolation was employed in an attempt to discover anti-TB NPs.  
Bioassay-guided isolation is the incorporation of bioactivity testing throughout the 
purification process to guide the isolation of bioactive compounds.51 Accordingly, testing for 
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bioactivity is performed early in the isolation process in order to identify and prioritise 
bioactive extracts for further purification.51 Bioactivity testing is then included at all 
subsequent fractionation steps, ensuring that isolated NPs are biologically active.51 
Depending on the aims of the research, extracts can be subjected to specific bioassays or 
screened using a variety of bioassays to get an indication of the bioactivity profile.52 In this 
study, the aim was to investigate NPs with anti-TB activity, and hence specific bioassays were 
used to guide isolation. 
In the following sections, an overview of a general NPs isolation process will be described, 
highlighting the processes of preparing crude extracts from bacterial cultures, bioactivity 
testing, liquid-liquid partitioning, prefractionation, dereplication, isolation, structure 
elucidation and chemical synthesis.  
 
1.3.1 Crude extracts from bacterial cultures 
 
Varying the bacterial culture conditions is known to influence the bacterial production, i.e. 
the yields and variety, of NPs.53 Numerous culture parameters can be altered that affect the 
production of NPs including aeration, incubation temperature and the nutrient composition 
of growth media.54 Nutrient deficient cultures, cultures lacking in a supply of carbon and 
nitrogen metabolites, have been shown to induce production of antibiotics.55 This nutrient 
deficiency can be due to low nutrient concentration in growth media or by exhaustion of 
nutrients during culture incubation.53 In this study, the growth medium, incubation volume 
and incubation time of actinobacterial cultures were varied. Crude extracts were prepared 
from bacterial cultures by solvent extraction using ethyl acetate (EtOAc) and methanol 
(MeOH) or through the use of XAD16 resin (Sigma). The use of XAD16 resin is a form of solid 
phase extraction in which hydrophobic molecules in a specific size range (up to 40 000 Mw) 
adsorb to the solid phase. The molecules can later be stripped from the resin by treating it 




1.3.2 Bioactivity testing 
 
Bioassays can be either biochemical or cell-based.52 Cell-based screening approaches have 
the advantage of screening for multiple targets in a single assay, while biochemical assays 
focus on a specific target.57 Lower activity is often observed in cell-based assays compared to 
biochemical assays, possibly due to poor membrane permeability, off-target effects and 
cytotoxicity.52 However, cell-based assays mimic in vivo conditions better than biochemical 
ones, identifying compounds that can be transported across or permeate through cellular 
membranes and interact with cellular components.52  
For the investigation of anti-TB NPs, cell-based assays such as bioautography and in vitro 
minimum inhibitory concentration (MIC) bioassays can be used, as in this study.45 
Bioautography can be performed against the test bacterium M. aurum A+. This is a fast, 
qualitative bioassay and can be used to identify extracts/compounds with potential activity 
against MTB.45 Compounds with activity against M. aurum A+ can then be rescreened against 
M. tuberculosis H37RvT to confirm anti-TB activity.58 Using these two assays in combination 
allows rapid screening of extracts/compounds for anti-TB activity.  
Bioassays can also be used to obtain a bioactivity profile of extracts/compounds. Although 
this was not the initial focus of this study, a bioactivity profile was obtained for extracts of a 
variety of S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T cultures. In 
vitro antibacterial and antifungal MIC bioassays were used to obtain the bioactivity profiles in 
a broad, untargeted approach.  
 
1.3.3 Liquid-liquid partitioning  
 
Crude extracts are complex mixtures of biological molecules containing a range of diverse 
NPs. To reduce the chemical complexity of such extracts, liquid-liquid partitioning can be 
employed. Liquid-liquid partitioning distributes solutes between two immiscible liquid phases 
of different polarity. By using a series of solvents with varying polarity, the extract can be 





Prefractionation is performed on crude extracts, separating extract components and yielding 
fractions each with reduced chemical complexity. Prefractionation can be achieved using 
several methods including anion exchange chromatography, column chromatography (such 
as flash chromatography) and high-performance liquid chromatography (HPLC). Anion 
exchange chromatography is used to separate compounds based on molecular charge, while 
flash chromatography and HPLC yield fractions containing compounds of different polarities.  
Fractions that result from prefractionation can be viewed as semi-purified since they 
commonly must undergo further purification to yield a pure isolated NP. Semi-purified 
extracts often display greater bioactivity than crude extracts, as compounds in these fractions 
are present in higher concentrations.59,60 However, the biological activity of compounds 




Dereplication is a multi-faceted tool used to accelerate the drug discovery process by the fast 
identification of known compounds.26 Efficient identification of known compounds in 
complex NP mixtures, i.e. crude and semi-purified extracts,  allows researchers to concentrate 
their efforts on the identification of unknown NPs.26 Tools used for dereplication include mass 
spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, or hyphenated 
combinations thereof, e.g. liquid chromatography-mass spectrometry (LC-MS), LC-NMR and 
LC-NMR-MS.26 The data obtained by dereplication can be compared to literature data in 
online databases, e.g. the Dictionary of Natural Products.61 
 
1.3.6 Isolation of pure compounds 
 
Isolation is performed to yield pure compounds and enable structure elucidation and 
bioactivity testing. A common chromatographic technique used for the isolation of pure 
compounds is HPLC. HPLC makes use of a liquid mobile and solid stationary phase. 
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Compounds are separated based on elution time, with elution time variance arising due to 
binding affinities to the mobile and stationary phases. The variable binding affinities are 
attributed to different binding forces between individual compounds and the two phases i.e. 
hydrogen bonding, Van der Waals forces and dipole-dipole interactions. Stronger binding 
affinity to the stationary phase results in a longer retention time and vice versa. Reversed 
phase HPLC (RP-HPLC) is frequently used for the isolation of NPs. In RP-HPLC, non-polar C18 
(octadecyl) can be used as a stationary phase.59 Hence, a non-polar mobile phase is required 
for the elution of non-polar compounds, as these compounds adhere strongly to the 
stationary phase.59 HPLC can be time-consuming, involving multiple injections, as each 
purification sequence is performed on small sample amounts.59 Isolation of NPs is often 
performed using semi-preparative HPLC, which employs columns that can separate larger 
sample masses per run than analytical HPLC.62  
The elution of NPs by HPLC can be monitored by ultraviolet (UV) light. UV chromatograms 
generated can be used to guide collection of compounds that absorb UV light, a chemical 
property that is dependent on the presence of a conjugated system of pi-electrons.59 
Therefore, a disadvantage of this technique is that compounds that do not absorb UV light 
will not be detected and can contaminate fractions collected by UV-guided HPLC. 
 
1.3.7 Structure elucidation  
 
The structure elucidation of NPs can be achieved using different methods, such as MS (low 
resolution or high resolution), NMR, UV/visible spectroscopy and infrared absorption 
spectroscopy. The elucidation of NP structures usually requires the use of two or more of 
these techniques.  
 
1.3.7.1 MS analysis 
 
MS is an analytical tool used to identify compounds by the molecular or atomic masses of 
their constituents through the generation of molecular ions. Molecular ions can be separated 
based on their mass-to-charge ratio (m/z) to yield a mass spectrum. The mass spectrometer 
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consists of an ion source, a mass analyser and a detector.63 These components function to 
yield data on molecular mass, relative abundance of ions and isotope patterns of analysed 
compounds, which are used to calculate a suggested molecular formula and the level of 
unsaturation of compounds.63,64 Both LC-MS and gas chromatography MS (GC-MS) 
hyphenated tools were used for structure elucidation in this study. LC-MS is commonly 
employed in the analysis of polar compounds and GC-MS used for lipophilic compounds.65  
 
In this study, an ultra-performance liquid chromatography time of flight (UP-LC-ToF) system 
with electrospray ionisation (ESI) and microchannel plate (MCP) detector was used. Through 
the use of smaller stationary phase particles, higher mobile phase linear velocities and 
increased pressures, the UP-LC module allows better separation of a complex mixture of 
compounds than HPLC.66 After exiting the UP-LC module, the eluting compounds enter the 
ion source.67 Compounds entering the ion source are ionised by ESI, a broadly used ionisation 
technique effective for most samples.67 This ionisation is facilitated by electrical energy, 
transferring ions from a solution into the gaseous phase.67 The gaseous phase ions form in 
three steps: an electrically charged spray, significant reduction in droplet size and finally the 
liberation of fully desolvated ions.67 These gaseous phase ions are then subjected to MS 
analysis.67  
Ions with different m/z-values travel through the ToF analyser at different, but constant, 
velocities and therefore reach the detector at different times. This allows separation of ions 
based on their mass, as ions with less mass travel faster than ions of greater mass and reach 
the detector first. Ions exiting the quadrupole collide with and are recorded by the MCP 
detector. The MCP detector is an ion-counting detector that consists of several channel 
electron multipliers (CEMs) in a cluster. When ions collide with these CEMs, they release a 
secondary cascade of electrons, thereby amplifying the detected signal.63 The resulting ions 
are plotted as m/z versus relative abundance (%).64  
The GC-MS system used in this study had an electron impact (EI) ionisation system and a triple 
quadrupole mass separator. Unlike LC-MS, samples subjected to GC-MS must be volatile, 
while stable at the temperatures used for chromatography (up to 250℃ by our method). 
Volatile samples can be prepared by derivatisation of non-volatile samples e.g. alkylation, 
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trimethylsilylation and trifluoroacetylation.68 The choice of derivatising agent depends on the 
structure of the compound to be analysed. In this study an alkylating agent was used to yield 
methyl esters from acids of saturated long-chain fatty acids (LCFAs).69 In GC-MS, EI is an 
effective and commonly used ionisation technique for a variety of samples.70 This ionisation 
uses high-vacuum bombardment of analyte molecules by accelerated electrons and results in 
extensive fragmentation of most analytes.70 However, this ‘hard’ ionisation can render the 
molecular ion undetectable, posing a challenge for some analyses.70  
In the MS analyser, ions with different m/z are separated as they are transported through the 
triple quadrupole. Radio frequency (RF) voltage with direct current (DC) offset voltages are 
applied to the quadrupoles and only ions with a specific m/z-value are able to reach the 
detector for each set of voltage ratios. The voltage ratios can therefore be varied to scan for 
a range of m/z-values. Secondary fragmentation of primary ions, also known as parent ions, 
occurs in the reaction cell that separates the two quadrupole analysers, generating an MS2 
spectrum of selected parent ions.71 MS2 permits the acquisition of highly detailed ion 
fragmentation information with a higher level of molecular specificity and selectivity that 
allows discrimination between very similar compounds (for example fatty acids).72 GC-MS 
data are also highly reproducible and linked to comprehensive databases that allow easy 
identification of analytes.70  
 
1.3.7.2 NMR spectroscopy 
 
NMR spectroscopy is a technique used to analyse the chemical composition, structure and 
bonding of compounds using radio waves.73 Atomic nuclei that have unpaired valence 
electrons can be analysed by NMR. These atomic nuclei usually possess spin quantum 
numbers of 1/2 e.g. 1H, 13C, 15N, 19F and 31P.64 Nuclei in an NMR sample will have a spin 
orientation either parallel (+1/2) or antiparallel (-1/2) when placed in a uniform magnetic 
field. Subjecting the sample to a radio frequency pulse excites the nuclei and rotates the net 
magnetization away from the Z-axis. Relaxation of the nuclei releases a detectable NMR-
signal as it returns to equilibrium.64,73  
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Proton (1H), carbon (13C) and nitrogen (15N) NMR spectra provide information on chemical 
shifts, integrals, splitting patterns and coupling constants (J). Chemical shifts and integrals are 
used to deduce the nature and number of nuclei present in the sample analysed, while 
splitting and coupling constants give an indication of the spatial arrangement of nuclei.74  
 
1H and 13C NMR are common one-dimensional (1D) techniques. These 1D techniques can be 
supplemented with two-dimensional (2D) NMR experiments to establish nuclei connectivity 
in a molecule. Commonly used 2D experiments are correlated spectroscopy (COSY), 
heteronuclear single-quantum correlation spectroscopy (HSQC) and heteronuclear multiple-
bond correlation spectroscopy (HMBC). COSY is used to identify proton spins that are coupled 
to one another. These proton-proton spin couplings are useful in mapping the proton network 
of the molecule. HSQC experiments indicate correlations between two different types of 
nuclei separated by one bond and HMBC detects long range correlations (typically 2 – 3 
bonds) between heteronuclear atoms. These heteronuclear experiments feature “through 
bond” couplings, usually between proton and carbon atoms. HMBC experiments are 
especially useful in determining the positions of quaternary carbon atoms, e.g. carbonyl 
carbon atoms. Some NMR experiments identify correlations between nuclei that are spatially 
near but separated “through space” by 2 – 5 Å. “Through space” NMR experiments include 
nuclear Overhauser effect spectroscopy (NOESY) and rotating frame nuclear Overhauser 
effect spectroscopy (ROESY). These two experiments are valuable in assigning the 
stereochemistry of a molecule.64 
 
1.3.7.3 Chemical synthesis 
 
Chemical synthesis has many uses in NP research. One use is the synthesis of a proposed 
structure to confirm the structure of an isolated compound, as was done in this study. If a 
compound of interest is produced in trace amounts insufficient for biological analysis, 
synthesis can also be used to address this supply issue. Additionally, isolated NPs can be used 
as leads in the creation of a compound library. Bioactivity testing of the synthesised library 
may reveal structure-activity relationships (SAR), which can facilitate the development of a 
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molecule exhibiting an optimised biological profile.75 Synthesis can either be performed de 
novo or by semi-synthesis using an NP as a scaffold. A successful example of antibiotics 
developed through the semi-synthesis of bacterial NP drug leads is the tetracyclines.75 The 
first tetracyclines were broad spectrum antibiotics isolated from actinomycete soil bacteria 
in 1948, but have since undergone semi-synthesis and SAR profiling to yield two more 
generations of tetracyclines with more potent bioactivities.75 
 
1.4 Aims of this thesis 
 
The aim of this study was to investigate the chemical diversity and biomedicinal potential of 
South African actinomycetes for TB drug discovery. In this endeavour, we attempted to re-
isolate and determine the structure of the compound named PK-B, produced by the novel 
South African actinomycete, S. speibonae PK-BlueT.45 In addition, S. speibonae PK-BlueT and 
two other South African actinomycete strains that have shown activity against M. aurum A+, 
namely, S. africanus CPJVR-HT and S. pharetrae CZA14T, were used in our efforts to isolate, 
purify and characterise potentially new anti-TB compounds. The objectives are to employ a 
bioassay guided isolation approach, as described in Section 1.3, incorporating the preparation 
of crude extracts from bacterial cultures, bioactivity testing, liquid-liquid partitioning, 











Chapter 2: Methods 
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Three different South African actinobacterial strains, S. speibonae PK-BlueT, S. africanus 
CPJVR-HT and S. pharetrae CZA14T, were examined for bioactive NPs. An effort was also made 
to re-isolate the compound named PK-B from S. speibonae PK-BlueT.45 These three bacterial 
strains were cultivated using various culture conditions, and different solvent extraction 
methods were investigated to prepare extracts for bioassay-guided isolation and 
dereplication. Fractions of interest were subjected to purification by liquid-liquid partitioning 
followed by HPLC and/or benchtop column chromatography. The structures of purified 
compounds were elucidated using NMR, high resolution (HR) LC-MS and GC-MS. Where 
required, confirmation of the structure was determined by synthesis of the compound. 
 
2.1 Culture conditions 
 
S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T were cultured under 
various culture conditions where three different parameters i.e. nutrient medium, culture 
volume and incubation time, were altered. Two different growth media were tested: Hacène’s 
medium76 (HM) (5 g glucose; 10 g malt extract; 2 g yeast extract; 1 g sodium chloride (NaCI); 
water (H2O) to 1 L; pH 7.0) and International Streptomyces Project 2 medium (ISP 2) (10 g malt 
extract; 4 g yeast extract; 4 g glucose; H2O to 1 L; pH 7.2 ± 0.2).77 All solid media were prepared 
by adding 1.5% (w/v) agar to liquid nutrient media. 
Three general culture conditions, HM large-scale, ISP 2 small-scale and ISP 2 large-scale, were 
implemented. The incubation time of each general culture condition was varied from 4 days 
(d) to 18 d. All cultures were tested for contamination by Gram staining, optical microscopy 
and by streak-plating for single colonies on agar medium (HM or ISP 2). Cultures were 
maintained on agar medium from which 20% glycerol spore suspensions were prepared for 
long term storage at -20˚C. 
S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T were also cultivated 
using a method obtained at the Helmholtz Institute for Pharmaceutical Research Saarland 
(HIPS). Three growth media were tested, namely tryptic soy broth (TSB) (17 g casein peptone; 
5 g NaCl; 3 g soy peptone; 2.5 g glucose; 2.5 g dipotassium phosphate; H2O to 1 L; pH 7.3 ± 
0.2),78 Streptomyces hagronensis growth medium (SHG) (20 g corn flour; 20 g glycerol; 10 g 
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soluble starch; 2 g calcium carbonate (CaCO3); H2O to 1 L; pH 7.5)79 and NL2 (30 g starch; 20 
g molasses; 15 g soy flour; 10 g CaCO3; 2.5 g yeast extract; H2O to 1 L) (Sanofi). All inoculations 
into TSB, SHG and NI2 were performed in a laminar flow fume hood and all cultures were 
tested for contamination by streak-plating for single colonies on agar medium. Cultures were 
maintained on agar medium from which 20% glycerol spore suspensions were prepared for 
long term storage at -20˚C. 
See sections 2.1.1 – 2.1.4 for details of the different culture conditions. 
 
2.1.1 HM large-scale culture method 
 
A 1 mL, 20% glycerol stock culture of S. speibonae PK-BlueT was used to inoculate a 100 mL 
Erlenmeyer flask containing 15 mL HM broth and incubated at 30˚C for 3 d with constant 
shaking. The resultant ISP 2 broth culture was used to inoculate a 1 L Erlenmeyer flask 
containing 100 mL HM broth and incubated at 30˚C for 4 d with constant shaking. Finally, the 
100 mL HM broth culture was inoculated into a 5 L Erlenmeyer flask containing 1 L HM broth 
and incubated at 30˚C for 4 d with constant shaking. 
 
2.1.2 ISP 2 small-scale culture method 
 
A 1 mL, 20% glycerol stock culture of S. speibonae PK-BlueT was used to inoculate a 250 mL 
Erlenmeyer flask containing 15 mL ISP 2 broth and incubated at 30˚C for 4 d with constant 
shaking. The resultant ISP 2 broth culture was used to inoculate a 1 L Erlenmeyer flask 
containing 100 mL ISP 2 broth and incubated at 30˚C for 4 d with constant shaking. Finally, 10 
mL of the 100 mL ISP 2 broth culture was used to inoculate each of 10 1 L Erlenmeyer flasks 
containing 100 mL ISP 2 broth and incubated at 30˚C with constant shaking. The incubation 




2.1.3 ISP 2 large-scale culture method 
 
A 1 mL, 20% glycerol stock culture of S. speibonae PK-BlueT was used to inoculate a 250 mL 
Erlenmeyer flask containing 15 mL ISP 2 broth and incubated at 30˚C for 4 d with constant 
shaking. The resultant ISP 2 broth culture was used to inoculate a 1 L Erlenmeyer flask 
containing 100 mL ISP 2 broth and incubated at 30˚C for 4 d with constant shaking. This ISP 2 
broth culture was inoculated into a 5 L Erlenmeyer flask containing 1 L ISP 2 broth and 
incubated at 30˚C with constant shaking. The incubation duration of the final culture step was 
14 d or 18 d. 
 
2.1.4 HIPS culture method 
 
A 3 mL, 20% glycerol stock culture was used to inoculate a 50 mL Erlenmeyer flask containing 
10 mL culture medium and incubated at 28˚C for 2 d with constant shaking. The resultant 
broth culture was inoculated into a 300 mL Erlenmeyer flask containing 100 mL culture 
medium and incubated at 28˚C for 4 d with constant shaking. Finally, the 100 mL broth culture 
was inoculated into a 5 L Erlenmeyer flask containing 1 L culture medium broth and incubated 
at 26˚C for 10 d with constant shaking. Sterile XAD16 resin in H2O (30 % v/v, Sigma) (30 mL) 
was added to the culture for the last 12 h of incubation. 
 
2.2 Solvent Extraction 
 
Three solvent extraction methods were used: solvent extraction of S. speibonae PK-BlueT HM 
broth cultures as outlined by Kirby,45 a general method of solvent extraction for S. speibonae 
PK-BlueT ISP 2 broth cultures and a HIPS extraction method. See sections 2.2.1 – 2.2.3 for 
descriptions of the solvent extraction methods. 
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2.2.1 Solvent extraction method for S. speibonae PK-BlueT HM broth cultures 
 
Solvent extraction was performed using the method outlined by Bronwyn Kirby.45 A 500 mL 
S. speibonae PK-BlueT HM broth culture was filtered through a paper coffee filter and the pH 
of the culture filtrate was adjusted to pH 2 with 1 M HCl. The acidified culture filtrate was 
extracted with EtOAc (150 mL), shaken vigorously in a separating funnel and the phases 
allowed to separate. The acidified, EtOAc extracted culture filtrate fraction was then flash-
frozen and lyophilised to yield the culture filtrate extract. 10% of the EtOAc layer was 
concentrated in vacuo and set aside for bioassay (crude EtOAc extract) and the remainder 
added to 500 mL sterile 10 mM Tris-HCl (pH7), shaken vigorously, and separated using a 
separating funnel. The organic layer was concentrated in vacuo to yield the final EtOAc 
extract. The aqueous layer was flash-frozen and lyophilised to yield the PK-B extract.45 The 
cell mass was extracted with MeOH (3 x 150 mL), shaken for 10 minutes each time, and then 
filtered through a paper coffee filter. The filtered organic liquid was concentrated in vacuo to 
yield the crude MeOH extract. The cell mass was discarded. 
 
2.2.2 General solvent extraction method for actinomycete broth cultures 
 
Actinomycete ISP 2 broth cultures were filtered through a paper coffee filter. The culture 
filtrate was extracted with EtOAc (3 x 30% of the culture volume) using a 2 L separating funnel. 
The organic layers were combined and concentrated in vacuo to yield the crude EtOAc extract. 
The culture filtrate aqueous layer was flash frozen and lyophilised to yield the crude aqueous 
extract. 
MeOH (3 x 20% of the culture volume) was added to the filtered actinobacterial cell mass 
(scraped off the coffee filter), shaken for 10 minutes each time and then filtered through a 
paper coffee filter. The filtered organic liquid was concentrated in vacuo to yield the crude 




2.2.3 HIPS Solvent Extraction 
 
The 1 L culture from the 5 L Erlenmeyer flask containing 30 mL sterile XAD16 resin in H2O (30 
% v/v, Sigma) was centrifuged and the supernatant discarded. MeOH (2 x 250 mL) was added 
to the combined cell mass and XAD16 resin, shaken for 2 h, filtered through glass wool 
(Sigma), and the two organic extracts combined and concentrated in vacuo. Dry extracts were 
immediately subjected to liquid-liquid partitioning as described in section 2.5.1.  
 
2.3 Biological assays 
 
Three different bioassays were performed i.e. bioautography against M. aurum A+, in vitro 
MIC90 anti-TB bioassay against M. tuberculosis H37RvT and in vitro MIC50 bioassay against a 
panel of test organisms at HIPS. Bioautography and MIC50 bioassays at HIPS were performed 
by the author, while MIC90 bioassays against M. tuberculosis H37RvT were done on the 
author’s behalf at the Institute of Infectious Disease and Molecular Medicine (IDM) at UCT. 
See sections 2.3.1 – 2.3.3 for specifics of the three bioassays performed. See Table 2.1 for a 










Table 2.1: Full bioassay screening panel used in this study. Crude extracts, partitioned 
fractions and pure compounds were tested for antimycobacterial, antibacterial and antifungal 
activity against a range of test organisms, employing three different bioassay techniques. 
Bioactivity Test microorganism Bioassay 
Antimycobacterial 
M. aurum A+ 
Cellular 
(Bioautography) 
M. tuberculosis H37RvT Cellular (MIC90) 
M. smegmatis mc2155 Cellular (MIC50) 
Antibacterial 
Escherichia coli DSM-1116 (WT) Cellular (MIC50) 
E. coli DSM-26863 (tolC3) Cellular (MIC50) 
Staphylococcus aureus ATCC-29213 Cellular (MIC50) 
Pseudomonas aeruginosa DSM-24600 Cellular (MIC50) 
Bacillus subtilis DSM-10T Cellular (MIC50) 
Antifungal 
Candida albicans DSM-1665 Cellular (MIC50) 





2.3.1 Bioautography against M. aurum A+ 
 
EtOAc, MeOH and aqueous extracts of S. speibonae PK-BlueT were tested for 
antimycobacterial activity against M. aurum A+ through the use of bioautography. 
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Bioautography was performed using the method described by Kirby.45 M. aurum A+ was 
streak-plated onto 2 x yeast extract tryptone agar (2YT)(16 g tryptone; 10 g yeast extract; 5 g 
NaCl; H2O to 1 L; pH 7)80 from a 20% glycerol stock culture and incubated at 37˚C for 3 d. One 
loopful of M. aurum A+ from this 2YT agar culture was used to inoculate a 20 mL universal 
container containing 5 mL 2YT broth, which was then incubated at 37˚C for 2 d with constant 
shaking.  
Dry extracts, see sections 2.2.1 and 2.2.2, were dissolved in MeOH (0.5 mL) and 10 μL spotted 
on thin layer chromatography (TLC) plates (aluminium-backed pre-coated silica gel 60 F254 
sheets, Merck). Rifampicin (0.6 μL, 8.4 mg/mL) was used as a positive control. The TLC plates 
were dabbed with an M. aurum A+ 2YT broth culture, with an optical density at 600 nm 
(OD600) adjusted to 0.5, using sterile Dove cotton wool pads. The loaded TLC plates were 
placed on water-dampened tissue paper in a sealed plastic container and incubated at 37˚C 
for 24 h. After incubation, the TLC plates were dabbed with 0.25% thiazolyl blue tetrazolium 
bromide (MTT) (Sigma) in phosphate buffered saline (1.78 g Na2HPO4; 8.50 g NaCl; 1 L distilled 
H2O; pH 7.3), resealed and incubated at 37˚C for a further 1 h. 
 
2.3.2 In vitro MIC90 M. tuberculosis H37RvT bioassay 
 
M. tuberculosis H37RvT MIC90 bioassays were performed on my behalf at the UCT IDM unit 
in a biosafety level 3 laboratory using the broth microdilution method described by 
Jorgensen et al.81 with a modified plate method.82 A 10 mL of M. tuberculosis H37RvT was 
grown to an OD600 of 0.6 – 0.7 in Middlebrook 7H9 medium (M7H9) (4 mL glycerol; 2 vials 
M7H9 ADC growth supplement (Sigma); H2O to 1 I; pH 6.6 ± 0.2)83 supplemented with 0.03 
% casitone, 0.4 % glucose and 0.05 % tyloxpol.84 The culture was diluted 1:500. Dry samples 
were reconstituted in dimethyl sulfoxide (DMSO) (1 mg/mL) then added to a 96-well 
microtitre plate (50 μL). The activity of a blank with only DMSO was not reported. The test 
material was diluted in a duplicated two-fold serial dilution with the M. tuberculosis H37RvT 
culture across 10 wells. The microtitre plate was sealed in a secondary container and 
incubated at 37˚C with 5% carbon dioxide (CO2) and humidification for 6 d after which 
Alamar Blue reagent was added to each well and the microtitre plate re-incubated for 24 h. 
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The assay was then scored visually with the lowest concentration of material displaying no 
visible growth scored as the MIC90. A minimum growth control (Rifampicin at 2 x MIC: 0.150 
μM), a maximum growth control (DMSO), and a rifampicin dose response (range 0.15 – 
0.0002 μM) were used. Relative fluorescence (excitation 540 nm; emission 590 nm) was 
measured using a SpecraMax i3x Plate reader at day 7 and analysed using Softmax Pro 6 
software.  
 
2.3.3 HIPS Bioassay 
 
Crude extracts and liquid-liquid partitioned fractions, i.e. the hexane, chloroform (CHCl3), 
H2O, and EtOAc fractions, were tested against a panel of bacteria and fungi. All bioassay 
procedures were conducted in a Biological Safety Cabinet in a biosafety level 2 laboratory. 
The test organisms were the bacteria Escherichia coli wild type (WT) (DSM-1116), E. coli tolC3 
(DSM-26863), Staphylococcus aureus ATCC-29213, Pseudomonas aeruginosa DSM-24600, 
Bacillus subtilis DSM-10T and M. smegmatis mc2155, and the fungi Candida albicans DSM-
1665 and Mucor hiemalis. M7H9 medium was used as the screening medium for M. 
smegmatis.83 Mueller-Hinton broth (MHB) (17.5 g Casein hydrolysate; 2 g beef extract; 1.5 g 
starch; H2O to 1 L; pH 7)85 was used for the remaining bacterial strains and Mycosel medium 
(Myc) (10 g Papaic Digest of Soybean Meal; 10 g glucose; 0.4 g cycloheximide; 0.05 g 
chloramphenicol; H2O to 1 L; pH 5.6 ± 0.2)86 was used for fungal strains. 
The test organisms were cultured at 30˚C overnight in 50 mL Falcon tubes containing 20 mL 
screening medium. The OD600 of each overnight culture was measured. These cultures were 
inoculated into 50 mL Falcon tubes containing 20 mL of the respective screening medium to 
an OD600 of 0.01 (bacteria), 0.05 (M. smegmatis) and 0.02 (fungi). Cultures were transferred 
to sterile 96-well microtitre plates (150 μL per well, 1 plate per strain) using a multichannel 
pipette. Extracts were dissolved in MeOH and 20 μL added to row A of each plate to yield a 
concentration of 640 μg/mL. A multichannel pipette was used to perform an extract dilution 
series to obtain extract concentrations of 640 μg/mL, 320 μg/mL, 160 μg/mL, 80 μg/mL, 40 
μg/mL, 20 μg/mL, 10 μg/mL and 5 μg/mL across the plate. Pure MeOH was used as a control. 
All plates were wrapped with Parafilm and placed on a Heidolph Titramax 1000 microplate 
shaker. Plates were incubated at 30˚C and 800 rpm. All plates were incubated for 16 h except 
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M. smegmatis which was incubated for 24 h., while M. hiemalis was incubated for a further 
24 h at room temperature, without shaking. MIC50 values were assigned by visually estimating 
a 50% zone of inhibition i.e. plate wells were visualised under a microscope and the 
concentration threshold determined at which 50% of the plate surface was cleared of 
microbial growth. Semi-purified extracts and pure compounds were rescreened for activity 




Dereplication was performed using low resolution (LR) LC-MS at UCT and HR LC-MS at HIPS. 
Details of dereplication methods using these two instruments are given in sections 2.4.1 – 
2.4.2.    
 
2.4.1 LR LC-MS dereplication 
 
Dereplication of culture extracts was performed by LC-MS. LC-MS samples were prepared by 
dissolving culture extracts in MeOH (10 mg/mL). Samples were run on an LR Agilent 
Technologies HPLC system. This system consisted of an Agilent Technologies 1260 Infinity 
Binary Pump, Agilent Technologies 1260 Infinity diode array detector (DAD), Agilent 
Technologies 1290 Infinity Column Compartment, Agilent Technologies 1260 Infinity Standard 
Autosampler and Agilent Technologies 6120 Quadrupole LC/MS. All dereplication was 
performed using a Zorbax, 300SB-C18 column (4.6 x 150 mm, 5 μm). All solvents used for 
HPLC were of HPLC grade (Merck or Sigma). Data was analysed using Agilent Technologies 
OpenLAB CDS ChemStation software. 
 
Samples were analysed using both positive-ion and negative-ion ESI MS. Extracts containing 
molecular masses abundant in active extracts, while absent in inactive extracts and 
uninoculated growth media, were investigated further. These molecular masses were 
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compared with the Dictionary of Natural Products and StreptomeDB databases to establish if 
they could be known compounds.61,87  
 
2.4.2 HR LC-MS dereplication 
 
Crude extracts and liquid-liquid partitioned fractions, i.e. hexane, CHCl3, H2O and EtOAc, were 
dissolved in MeOH. HR LC-MS mass spectra were obtained on an Agilent 1200 series HPLC-UV 
system combined with an ESI-ToF-MS (Maxis, Bruker) using a Waters Acquity UP-LC BEH 
column (2.1 x 50 mm, 1.7 μm). Data was analysed using Thermo Scientific Chromeleon 
Chromatography Data System software. HR LC-MS data were compared with growth media 
HR LC-MS data and with the Dictionary of Natural Products database.61  
 
2.5 Purification of extracts 
 
Crude EtOAc extracts were subjected to an initial purification process of liquid-liquid 
partitioning, which is described in section 2.5.1. Fractions obtained from liquid-liquid 
partitioning were then further purified by semi-preparative HPLC and/or benchtop column 
chromatography as required to obtain pure compounds. Here, semi-preparative HPLC was 
used for the purification of chemically complex extracts and benchtop column 
chromatography, as required, was used for the purification of extracts with few components 
and a significant amount of material. A third chromatographic technique, anion exchange 
chromatography, was used for the separation of charged molecules. For details of the 
chromatographic techniques used see sections 2.5.2 – 2.5.4. 
 
2.5.1 Liquid-liquid partitioning 
 
Crude EtOAc extracts were dissolved in 200 mL MeOH and partitioned with 3 x 200 mL hexane 
using a separating funnel. The hexane fraction was concentrated under vacuum to yield the 
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hexane extract. The MeOH fraction was concentrated under vacuum, reconstituted in 200 mL 
H2O and extracted with 3 x 200 mL CHCl3, followed by 3 x 200 mL EtOAc. The H2O, CHCl3 and 
EtOAc partitions were individually concentrated under vacuum to yield the H2O, CHCl3 and 
EtOAc extracts, respectively. 
 
2.5.2 Semi-preparative HPLC 
 
For semi-preparative HPLC, the acetonitrile used was of HPLC grade (Merck or Sigma), while 
H2O was filtered (0.22 μm membrane filter). Both the H2O and acetonitrile were 
supplemented with 0.1% trifluoroacetic acid (TFA) or 0.1% formic acid (FA) (Sigma). Semi-
preparative HPLC at UCT was performed using an Agilent Technologies 1200 series HPLC 
system equipped with an Agilent Technologies 1200 series quad pump and Agilent 
Technologies 1200 series DAD. Samples were analysed using a Phenomenex Luna C18(2) (10 
μm, 250 x 10 mm) column or a Develosil Diol-100 column (5 μm, 4.6 x 150 mm). 
At HIPS, HPLC was performed on liquid-liquid partitioned extracts using a Gilson HPLC system 
(Gilson 322 pump, Gilson UV/Vis-151 detector and Gilson 402 syringe 3 pump). HPLC 
gradients were developed using a Phenomenex Jupiter Proteo LC column (250 x 4.60 mm, 4 
μm) then samples separated using a Phenomenex Jupiter Proteo LC column (250 x 10 mm, 4 
μm).    
 
2.5.3 Benchtop column chromatography 
 
Solvents used for benchtop column chromatography were analytical reagent (AR) grade that 
had been further purified by distillation. Benchtop columns were performed using silica gel 
60 (Fluka 70 – 230 mesh, 63 – 200 µm) (Sigma) and monitored by TLC using aluminium-backed 
pre-coated silica gel 60 F254 sheets (Merck). TLC plates were viewed under UV light (254 nm 
and 330 nm) and developed using either ceric ammonium sulphate or 1:1 concentrated H2SO4 
and MeOH stain, both followed by heating. 
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2.5.4 Anion Exchange Chromatography 
 
Whatman DE52 Matrix was prepared in 100 mM Tris-HCl (pH7) according to the 
manufacturer’s instruction and packed into a 10 mL glass pipette. The packed column was 
washed with 30 mL 10 mM Tris-HCl (pH7). 
The lyophilised S. speibonae PK-BlueT HM broth culture extract was dissolved in 2 mL sterile 
H2O, diluted with 10 mL 10mM Tris-HCl (pH7), the pH adjusted to pH7 and applied to the 
column. A step gradient of 20 mL of each of 20, 50, 100, 250, 500 and 1000 mM NaCl in 10 
mM Tris-HCl (pH7) was used sequentially and then the column was flushed with 2.5 M NaCl 
in 10 mM Tris-HCl (pH7). 22 x 5 mL fractions were collected and individually concentrated in 
vacuo. 
 
2.6 Structure elucidation 
 
The structures of purified compounds were determined by HR LC-MS and GC-MS, NMR 
analysis, UV spectroscopy, and, where required, confirmed by synthesis of the compound. 
These techniques are detailed in sections 2.6.1 – 2.6.5. 
 
2.6.1 HR LC-MS 
 
For HR LC-MS analysis, pure compounds were dissolved in HPLC grade solvent. HR LC-MS data 
for UCT samples was obtained using a Waters Synapt G2 LC-ToF-MS instrument at the 
Stellenbosch University Central Analytical Facility (CAF) or a Thermo Instruments MS system 
(LTQ XL/LTQ Orbitrap Discovery) coupled to a Thermo Instruments HPLC system (Accela PDA 
detector, Accela PDA autosampler and Accela pump) at the University of Aberdeen Marine 
Biodiscovery Centre. HR LC-MS data for HIPS samples was obtained using a Bruker maXis 4G 





Lipid compounds were derivatised for GC-MS according to the method described by Ichibara 
and Fukubayashi.69 Toluene (0.2 mL), MeOH (1.5 mL), and an 8% (w/v) solution of HCl in 
MeOH/ H2O (85:15, v/v) (0.3 mL) were added sequentially to the lipid compound(s). The 
resulting solution was vortexed then incubated overnight at 45°C. After cooling to room 
temperature, H2O (1.0 mL) and hexane (1.0 mL) were added, followed by vortexing. The 
hexane layer was collected and analysed by GC-MS using an Agilent Technologies J&W column 
(30 m x 250 μm x 0.25 μm) on an Agilent Technologies 7890A GC system equipped with an 
Agilent Technologies 7693 Autosampler and Agilent Technologies 7000A GC/MS Triple 




Pure compounds were dissolved in 160 μL deuterated methanol (MeOH-d4) or chloroform 
(CDCl3) NMR solvent for NMR analysis (Sigma). NMR data were collected using a Bruker 600-
MHZ spectrometer equipped with a 5-mm Prodigy cryoprobe. Chemical shifts are reported in 
ppm and spectra referenced to residual solvent resonances (CDCl3 δH 7.26, δC 77.0, MeOH-d4 
δH 3.30, δC 49.0).88 Coupling constants (J) are reported in Hertz (Hz). 
 
2.6.4 UV Spectroscopy 
 
UV absorption data was obtained using an Agilent Technologies Cary 60 UV-Vis spectrometer. 
Samples were dissolved in MeOH (0.5 mg/mL) for analysis and molar extinction coefficients 
calculated using the Beer-Lambert law.89 
 
2.6.5 Chemical Synthesis 
 
All reagents used in synthesis were purchased from Sigma. Reaction mixtures were heated 
using an oil bath and the reaction progress monitored by TLC. Upon completion of the 
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reaction, reaction mixtures were dissolved in 1 M sodium hydroxide (NaOH), extracted into 
EtOAc, and the organic extract washed with saturated sodium bicarbonate (NaHCO3) before 
drying over magnesium sulfate (MgSO4). Products were concentrated in vacuo. See section 












Chapter 3: Results and discussion 
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The primary objective of this study was the re-isolation and structure elucidation of the 
antimycobacterial compound PK-B from the South African actinomycete, S. speibonae PK-
BlueT, following the method outlined by Kirby.45 This chapter summarises the efforts made to 
achieve this objective and discusses potential reasons for the fact that it ultimately proved 
unsuccessful. Owing to difficulties in reproducing the previously reported results, culture 
conditions suitable for the production of other antimycobacterial compounds by S. speibonae 
PK-BlueT were explored, with success. These culture conditions were implemented in the 
bioassay-guided isolation of compounds from S. speibonae PK-BlueT extracts. Purification of 
S. speibonae PK-BlueT extracts resulted in the isolation of the alkaloid, N-phenylpyridin-2-
aminium (3.1); the fatty acids, n-hexadecanoic acid (3.2) and 14-methylpentadecanoic acid 
(3.3); and the isoflavone, 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one (3.4). The 
biological activity of these compounds against M. tuberculosis H37RvT was also determined. 
In addition to S. speibonae PK-BlueT, two other bacterial strains, namely S. africanus CPJVR-
HT and S. pharetrae CZA14T, were investigated for the production of bioactive NPs. All three 
strains were analysed at UCT, and also during a six-week internship at the Helmholtz Institute 
for Pharmaceutical Research Saarland (HIPS). Section 3.1 describes the strategies 
implemented in the bioactivity-guided isolation of compounds at UCT, while the investigation 
of the same strains at HIPS is covered in section 3.2. 
 
3.1 Streptomyces speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T at 
UCT 
 
This section provides details of the work performed on the three South African actinomycetes 
S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T at UCT.  
 
3.1.1 Attempted re-isolation of compound PK-B  
 
The initial attempt to re-isolate compound PK-B from S. speibonae PK-BlueT was performed 
by replicating the method described by Kirby.45 Streptomyces speibonae PK-BlueT was 
cultivated in 1L HM broth, as described in section 2.1.1. After incubation, the culture was 
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subjected to the prescribed method of solvent extraction using EtOAc and MeOH to yield five 
crude culture extracts; i.e., the extracted culture broth, crude EtOAc extract, final EtOAc 
extract, MeOH extract and PK-B extract. The PK-B extract was reported by Kirby to contain 
compound PK-B; however, as a precaution, all five extracts were tested for bioactivity. 
Mycobacterium aurum A+ was used as the bioautography test organism (see section 2.3.1), 
as compound PK-B was reported to have activity against this bacterium.45 Unfortunately, 
none of the extracts displayed activity against M. aurum A+. The process was repeated three 
times to exclude any potential errors that could result in a change in the NPs produced, such 
as inadvertent changes in the culture conditions i.e. incubation temperature and constant 
shaking for aeration; however, repeated attempts yielded no extracts with activity against M. 
aurum A+. 
As it was possible that the negative bioassay result was due to compound PK-B being a very 
minor component of the extracts, the PK-B extract was purified by anion exchange 
chromatography (see section 2.5.4), as reported by Kirby.45 This technique is used to separate 
compounds based on their charge and was performed at pH7, a pH at which PK-B is reported 
to be negatively charged.45 All 22 fractions resulting from the anion exchange 
chromatography were screened for activity against M. aurum A+; again, no activity was found. 
Since the extracts were not active against M. aurum A+, it was concluded that PK-B was not 
being produced under the implemented culture conditions. It was hypothesised that, at the 
end of the incubation period, the S. speibonae PK-BlueT culture had yet to reach stationary 
phase. If the S. speibonae PK-BlueT culture had not yet reached stationary phase, secondary 
metabolism and the production of antibiotic NPs might not have been activated. There is 
some evidence to support this hypothesis since the production of aerial mycelium in 
streptomycetes is linked to secondary metabolism and antibiotic production.90 Streptomyces 
speibonae PK-BlueT has also been shown to produce grey aerial mycelium on agar medium.91 
The production of this grey aerial mycelium on HM agar was consistently observed to coincide 
with the appearance of the blue colour in the substrate mycelium that gave rise to the species 
name, PK-Blue (see Figure 3.1). Streptomyces speibonae PK-BlueT is known to produce blue 
substrate mycelium,91 but failed to do so under the implemented culture conditions, a 
possible indication that the culture had not matured to the point of inducing secondary 
metabolism. It was further hypothesised that S. speibonae PK-BlueT cultures had stopped 
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producing PK-B due to the bacterium becoming accustomed to living on rich laboratory 
growth media. This adaptation to the rich laboratory growth medium could have resulted in 
S. speibonae PK-BlueT no longer expressing all the genes it expressed as a “wild” bacterium, 
as it is known that growth medium nutrient composition affects gene expression of bacteria 
and therefore antibiotic production.54 It was therefore decided that the culture conditions 
should be optimised for activity against M. aurum A+ by the induction of secondary 
metabolism through the use of an alternative growth medium using the appearance of blue 
mycelium as an indicator.   
 
 
Figure 3.1: Streptomyces speibonae PK-BlueT HM agar plate showing blue substrate 
mycelium after incubation at 30°C for 14 days. 
 
3.1.2 Optimisation of Streptomyces culture conditions for activity against M. aurum A+ 
 
ISP 2 medium was used as the growth medium for the optimisation of activity against M. 
aurum A+ in S. speibonae PK-BlueT cultures, as ISP 2 medium is commonly used in the culturing 
of actinobacteria. All cultures were incubated at 30°C with constant shaking while the final 
incubation culture volume and time were varied based on the time of appearance of the blue 
pigment in the mycelium. After incubation, a solvent extraction was performed (see section 
2.2.2) and the extracts tested for activity against M. aurum A+ by bioautography, as described 
in section 2.3.1. As a control, uninoculated, sterile ISP 2 broth medium was subjected to 
solvent extraction using the same method adopted for the cultured extracts and tested 
against M. aurum A+. 
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Both small- and large-scale S. speibonae PK-BlueT cultures were prepared. Small-scale cultures 
using a 1 L Erlenmeyer flask containing 100 mL ISP 2 broth culture incubated for a minimum 
of 7 d exhibited blue mycelia, with solvent extracts showing activity against M. aurum A+ (for 
full culture conditions see section 2.1.2). Large-scale S. speibonae PK-BlueT cultures using a 5 
L Erlenmeyer flask containing 1 L ISP 2 broth culture exhibited the same blue mycelium and 
activity against M. aurum A+ when incubated for a minimum of 14 d (culture conditions are 
detailed in section 2.1.3). Good activity against M. aurum A+, indicated by a significant zone 
of inhibition by bioautography, was consistently found in crude EtOAc extracts. However, 
weak activity against M. aurum A+ was observed for MeOH extracts and no activity observed 
in the extracted culture broth. This suggested that the bioactive compounds produced by S. 
speibonae PK-BlueT were secreted by the cells into the growth medium and are readily soluble 
in EtOAc. Active EtOAc extracts were then prioritised for purification as part of our strategy 
of bioassay-guided isolation of antimycobacterial compounds. 
The optimised large-scale culture conditions developed for S. speibonae PK-BlueT were used 
in the cultivation of S. africanus CPJVR-HT and S. pharetrae CZA14T. Cultures of these two 
actinobacteria were subjected to solvent extraction and the resulting crude EtOAc extracts 
were revealed to be active against M. aurum A+ by bioautography.  
 
3.1.3 Dereplication and liquid-liquid partitioning of bacterial extracts 
 
All bacterial extracts and an uninoculated, sterile ISP 2 broth medium EtOAc extract were 
analysed by LR LC-MS for dereplication (see section 2.4.1). The purpose of dereplication was 
to facilitate efficient identification of known compounds by comparing extract molecular 
masses against the Dictionary of Natural Products and StreptomeDB online databases.61,87 LR 
LC-MS was used in the dereplication process, as the instrument was readily available. Using 
such low-resolution MS data, which measures molecular ion masses to only one decimal 
place, is not ideal for dereplication of NPs. These data are not accurate enough to confidently 
assign molecular formulae to NPs, although they could be used to give an indication of the 
masses of the molecular ions present in the samples.  Ideally HR LC-MS data with an the 
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accuracy of four decimal places should be recorded as this can resolve differences between 
compounds with very similar m/z-values.92,93  
The LR LC-MS profiles of crude culture extracts, liquid-liquid partitioned fractions and pure 
compounds were compared with that of the uncultured, sterile ISP 2 broth medium EtOAc 
extract. An EtOAc extract of the sterile, uncultured ISP 2 broth medium (prepared using the 
method described in section 2.2.2) was used as a blank sample. For dereplication of the 
bioactive crude extracts and semi-purified extracts, the LC-MS ion molecular masses and 
retention times of major peaks were compared with that of the ISP 2 medium blank. This was 
done to confidently identify ions present in extract samples, but absent from the ISP 2 
medium blank. The knowledge gained by this comparison allowed purification efforts to be 
concentrated towards isolation of compounds of bacterial origin.  
The first purification step of bioactive crude EtOAc extracts was liquid-liquid partitioning with 
hexane, CHCl3, H2O and EtOAc (see section 2.5.1). Compounds in the extracts were partitioned 
into the four different solvents based on their polarity and therefore their solubility in the 
respective solvents. The hexane fraction, hexane being the least polar solvent, accumulated 
the least polar compounds. The H2O fraction, the most polar fraction, accumulated the most 
polar compounds. This is consistent with the principle that “like dissolves like”.62 Similarly, 
intermediate polarity compounds were partitioned between the two medium polarity solvent 
fractions of EtOAc and CHCl3. The liquid-liquid partitioning of crude extracts resulted in four 
fractions that were each less chemically complex than the parent fraction; i.e., containing a 
smaller variety of compounds. This can be seen by comparing LC-MS chromatogram profiles 
of a fraction resulting from liquid-liquid partitioning with its parent extract, and is illustrated 
in Figure 3.2. This figure displays an overlay of the positive-ion ESI LC-MS chromatograms (5 
– 95% acetonitrile) of an S. speibonae PK-BlueT crude EtOAc extract and liquid-liquid 
partitioned CHCl3 fraction, showing the decrease in chemical complexity after solvent 
partitioning. Figure 3.2 also illustrates that the CHCl3 fraction, as a medium polarity fraction, 
accumulated the compounds of intermediate polarity; i.e., compounds that eluted in the 




Figure 3.2: Overlay of the positive-ion ESI LC-MS chromatograms of an S. speibonae PK-BlueT 
crude EtOAc extract and liquid-liquid partitioned CHCl3 fraction (5 – 95% acetonitrile).  
 
All fractions from liquid-liquid partitioning were screened for activity against M. aurum A+ by 
bioautography as part of the strategy of bioassay-guided isolation of antimycobacterial 
compounds. Active fractions were selected for further purification and the individual 
purification strategies of compounds isolated from S. speibonae PK-BlueT are discussed in the 
following section. 
 
3.1.4 Compounds isolated from S. speibonae PK-Blue 
 
Four compounds were isolated from S. speibonae PK-BlueT using the culture conditions 
optimised for activity against M. aurum A+. The isolation and structure elucidation of these 
compounds, 3.1 – 3.4, are detailed below.  
 
3.1.4.1 Isolation and structure elucidation of N-phenylpyridin-2-aminium 
 
The antimycobacterial alkaloid, N-phenylpyridin-2-aminium (3.1, 2.5 mg), was isolated from 
a 14 d, ISP 2 small-scale culture of S. speibonae PK-BlueT (see section 2.1.2 for ISP 2 small-
scale culture method). An extensive review of the Scifinder database42 has shown that the 
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deprotonated form of this compound, N-phenylpyridin-2-amine (3.5),94 has previously been 





An EtOAc extract (145 mg) with bioactivity against M. aurum A+ (see Figure 3.3) was obtained 
from a 14 d S. speibonae PK-BlueT culture and was subsequently subjected to liquid-liquid 
partitioning. The CHCl3 fraction from liquid-liquid partitioning had activity against M. aurum 
A+ and hence this fraction was further purified by RP-HPLC (40 - 100% acetonitrile, 0.1% TFA 
in H2O). All fractions collected from RP-phase HPLC purification were tested for activity 
against M. aurum A+ and the bioactive compound 3.1 was shown to elute at 100% acetonitrile 




Figure 3.3: Bioautography against M. aurum A+ of an S. speibonae PK-BlueT crude EtOAc 
extract. Bioactivity is indicated by a clear yellowish zone of inhibition. Rifampicin was used as 





Scheme 3.1: Isolation protocol for 3.1 from S. speibonae PK-BlueT ISP 2 cultures. 
 
Data obtained by 13C and 1H NMR (see Figure 3.4) and HR LC-MS (molecular ion m/z = 
171.0918, ESI+) were used to deduce a molecular formula for 3.1 of C11H10N2 (for NMR and 
HR LC-MS methods see sections 2.6.1 and 2.6.3). 1D NMR spectroscopy (13C and 1H) showed 
all carbon and proton signals to be significantly deshielded and in the aromatic range, and 2D 
NMR experiments (COSY, HSQC, HMBC and NOESY) indicated that the aromaticity of the 
compound was due to two independent conjugated pi-electron systems. This information was 
used to initially assign the structure as (3.5). UV analysis indicated the presence of two 
conjugated aromatic systems absorbing at 265 nm and 310 nm, which was supported by NMR 
data. COSY and HMBC (Figures 3.5 and 3.6) correlations indicated the presence of two isolated 
aromatic ring systems; one phenyl group and one heteroaromatic six-membered ring. As the 
molecule was shown to be purely aromatic and all 13C/1H signals appeared in the downfield 
region of the NMR spectra, it followed that the two aromatic ring systems could not be 
bridged by a carbon atom. This was consistent with the deduced molecular formula and a 
nitrogen atom as the bridging atom (N-1) accounted for the observed molecular ion mass. 
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The heteroaromatic substituent was assigned as 2-pyridine based on COSY and HMBC 
correlations and the C-2 quaternary carbon signal (δc 153.8), which is characteristic for this 
type of system.95  
 
 




Figure 3.5: COSY spectrum (MeOH-d4, 600 MHz) of 3.1. The accompanying structure shows 
the key COSY correlations used to deduce the structure of 3.1. 
 
However, experimental 1D NMR data did not correlate with literature 1D NMR data of 3.5.94 
As the 2D NMR data strongly supported the assignment of 3.5, this compound and its 
protonated form 3.1 were synthesised (see section 4.2). By comparing NMR data of the 
isolated compound with that of both synthesised compounds, the isolated compound was 
assigned as compound 3.1 (see Figure 3.7). NMR data of the isolated and synthesised 3.1 
correlated well, but imperfectly. However, the assignment of the isolated 3.1 was further 
supported by LC-MS data. It was observed that the synthesised 3.1 and 3.5 both yielded 
49 
m/z=171.0 (ESI+) by LR LC-MS but with different retention times, and the retention time of 
the isolated molecule matched that of the synthesised 3.1. 
NMR prediction software (both ACD/Labs NMR Spectroscopy Software and Chemdraw 
Professional) was used to guide the approach of using chemical synthesis. As we were 
confident that the backbone of the structure was correctly identified (a phenyl ring and 
pyridine ring bridged by a nitrogen atom), it was hypothesised that the differences in chemical 
shifts between 3.1 and 3.5 was due to a protonation/deprotonation effect. This was 
supported by the NMR prediction software which showed that protonation of the bridging 
nitrogen of 3.5 would yield a compound with an NMR profile similar to 3.1, while protonation 
of the pyridyl nitrogen or both of the nitrogen atoms in the compound were predicted to 
create greater differences in the NMR profiles. This effect was observed experimentally after 
synthesis of 3.1, as literature NMR data on 3.1 were not available. As the experimental NMR 
data for the synthesised and isolated 3.1 were very similar but not perfectly so, it was 
considered that the slight discrepancy could be due to the degree of protonation, but titrating 
3.5 against acid and analysing by NMR did not show protonation of N-2 and this was not 
confirmed experimentally. Also, as there was insufficient material of the isolated 3.1, it was 
not possible to manipulate it with acid/base treatments. Another option that was considered 
for the observed differences between the synthesised and isolated 3.1 were a counter-ion 
effect. To investigate this, 3.5 was protonated using HBr and HCl, but these yielded the same 
result by NMR.  
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Figure 3.6: HMBC spectrum (MeOH-d4, 600 MHz) of 3.1. The accompanying structure shows 
the key HMBC correlations used to deduce the structure of 3.1. 
 
Figure 3.7: Overlay of 1H NMR spectra (MeOH-d4, 600 MHz) of the isolated 3.1, synthesised 
3.1 and synthesised 3.5. 
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During the structure elucidation of 3.1, LR LC-MS data of the parent fractions of the isolated 
3.1 were reviewed, but the molecular ion m/z = 171.0 was not found prior to HPLC 
purification. Hence there can be some debate as to whether 3.1 is produced by S. speibonae 
PK-BlueT or if it has another origin. Efforts were made to ascertain if the origin of this 
compound could be other than the S. speibonae PK-BlueT culture, but no plausible other 
source was identified. It was confirmed that compound 3.1 was not owned by any of the 
research groups in the buildings where work was performed. Additionally, the author was the 
only HPLC operator for two months prior to and after the isolation of this compound and the 
only samples purified were S. speibonae PK-BlueT extracts, making it unlikely that the 
compound arose from contamination during purification. It can therefore not be concluded 
that 3.1 is produced by S. speibonae PK-BlueT, however it also cannot be concluded that the 
bacterium is not the producer of the compound. A possible reason for not observing 3.1 in 
the parent fractions is that it could be the break-down product of another molecule produced 
by S. speibonae PK-BlueT and present in the crude EtOAc extract, although possible precursors 
were not identified in the parent fraction.  
 
3.1.4.2 Isolation and structure elucidation of n-Hexadecanoic acid and 14-
methylpentadecanoic acid 
 
The known saturated LCFAs, n-hexadecanoic acid (3.2) and 14-methylpentadecanoic acid 
(3.3), were isolated as a mixture (2.2 mg) from six culture broths of S. speibonae PK-BlueT, 
both small- and large-scale.96,97 The crude EtOAc extracts of these six cultures displayed 
activity against M. aurum A+ by bioautography and were subjected to liquid-liquid 
partitioning. The resulting liquid-liquid partitions – i.e., hexane, CHCl3, H2O and EtOAc – were 
screened for activity against M. aurum A+ by bioautography and the CHCl3 fractions were 
found to be active. The CHCl3 fractions were then individually semi-purified by RP-HPLC (40 - 
100% acetonitrile, 0.1% TFA in H2O). In each case, the RP-HPLC 100% acetonitrile wash 
showed activity against M. aurum A+. The six semi-purified wash fractions were then 
combined based on the similarity of their 1H NMR profiles and purified further by semi-
preparative RP-HPLC (20 - 100% acetonitrile, see section 2.5.2) to yield 3.2 and 3.3 as a 
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mixture (2.2 mg). The HPLC fraction containing the mixture of 3.2 and 3.3 exhibited activity 
against M. aurum A+ by bioautography. See Scheme 3.2 for the isolation protocol for 3.2, 3.3 






Scheme 3.2: Isolation protocol for 3.2, 3.3 and 3.4 from S. speibonae PK-BlueT ISP 2 cultures. 
 
1D NMR of the mixture of 3.2 and 3.3 showed the presence of a long-chain hydrocarbon, with 
a characteristic broad signal at δH 1.29 – 1.30 ppm and multiple signals at δC 30 – 31 ppm in 
addition to a characteristic carboxyl signal at δC 177.7, as seen in Figure 3.8.95 The mixture of 
3.2 and 3.3 was therefore expected to be a fatty acid. Fatty acids are commonly analysed by 
GC-MS, as this technique is highly sensitive and reproducible, and also allows the 
characterisation of complex mixtures of geometric isomers.98 Hence the sample was 
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derivatised to form the fatty acid methyl esters (FAMEs) before GC-MS was used to determine 
the length of the hydrocarbon chain (see section 2.6.2 for GC-MS derivatisation methods and 
protocols). GC-MS analysis showed hydrocarbon chain lengths corresponding to those of 3.2 
and 3.3, where they were present as methyl esters. The structures of 3.2 and 3.3 were 
supported by 2D NMR data (see Figure 3.9) and confirmed by comparison of experimental 




Figure 3.8: 1H (MeOH-d4, 600 MHz) and 13C (MeOH-d4, 150 MHz) NMR spectra obtained for 
the mixture of 3.2 and 3.3. EtOAc is present in the 13C NMR sample and accounts for the 
carboxyl signal observed at δC 172.99. 
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Figure 3.9: COSY spectrum (MeOH-d4, 600 MHz) of 3.2 and 3.3. The accompanying structures 
show the key COSY correlations used to deduce the structures of 3.2 and 3.3. 
 
3.1.4.3 Isolation and structure elucidation of 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-
one 
The known isoflavone, 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one (3.4, 0.6 mg),99 
was isolated from the same six S. speibonae PK-BlueT cultures (small- and large-scale) as 3.2 
and 3.3. The crude EtOAc extracts of these six cultures displayed activity against M. aurum A+ 
by bioautography. Subsequent liquid-liquid partitioning of the crude EtOAc extracts yielded 
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CHCl3 fractions with bioactivity against M. aurum A+. Semi-preparative RP-HPLC (40 - 100% 
acetonitrile, 0.1% TFA in H2O) was performed on the CHCl3 fractions. Activity against M. 
aurum A+ was found in the first fraction collected (40% acetonitrile, 0.1% TFA in H2O) and the 
HPLC UV chromatogram showed this to be a complex mixture of compounds. This first HPLC 
fraction from the six cultures was combined and analysed by TLC (see section 2.5.3). As the 
TLC profile was simple, the combined fraction was purified further by benchtop column 
chromatography (isocratic 50% hexane/EtOAc). 1H NMR showed that 3.4 was present, with 
minor peaks indicating the presence of impurities, in the second of seven fractions from 
benchtop column chromatography. This second fraction was further purified by semi-
preparative RP-HPLC (2 - 100% acetonitrile, 0.1% FA, see section 2.5.2) to yield 3.4 (0.6 mg). 
The isolation procedure of 3.4 is outlined in Scheme 3.2. 
The structure of 3.4 was determined using the LR LC-MS molecular ion mass of m/z = 255.0 
(ESI+) in conjunction with 1D and 2D NMR data (1H, 13C, COSY, HSQC and HMBC). 1H and 13C 
NMR data showed 3.4 to be purely aromatic due to the absence of upfield signals as seen in 
Figure 3.10. Correlations observed in a 2D COSY NMR experiment showed three aromatic spin 
systems which were pieced together based on the HMBC correlations to C-3, C-4, C-1’, and C-
8a (see Figure 3.11 and Figure 3.12). The chemical shift of C-4 (δc 178.2) was characteristic of 
a carbonyl group and the substituents at C-4’ and C-7 were based on their characteristic 
chemical shift values and to account for the molecular ion mass obtained by LR LC-MS.95 The 
structure of 3.4 was confirmed by comparison of experimental NMR data with literature NMR 















Figure 3.11: COSY spectrum (MeOH-d4, 600 MHz) of 3.4. The accompanying structure shows 
the key COSY correlations used to deduce the structure of 3.4. 
 
After the structure elucidation of 3.4, a literature search identified 3.4 as a demethylated 
conjugate of formononetin (3.6), a compound common to legumes such as soy beans and red 
clover.99 Therefore it was speculated that 3.5 was produced through the metabolism of 3.6, 
which was present as a component of the ISP 2 growth medium, rather than produced de 
novo by S. speibonae PK-BlueT. The most likely source of 3.6 is the 10 g/L of malt extract used 
in preparing ISP2 broth. Malt extract is prepared from malted barley. 
LR LC-MS data of an uninoculated, sterile ISP 2 broth medium EtOAc extract showed a 
molecular ion mass of m/z = 269.3 (ESI+), indicative of the presence of 3.6. The ability to 
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demethylate of 3.6 has been reported to be common among lactic acid bacteria and 






Figure 3.12: HMBC spectrum (MeOH-d4, 600 MHz) of 3.4. The accompanying structure shows 




3.2 S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T at HIPS 
 
During a six-week internship at HIPS, the three South African actinomycetes, S. speibonae PK-
BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T, were cultured and subjected to 
bioassay-guided isolation for the discovery of novel NPs. This internship was an excellent 
opportunity, as it allowed access to and training on different instruments and bioassays which 
were incorporated in the study, including first-hand experience of running HR LC-MS 
experiments and MIC50 bioassays. 
 
3.2.1 Culture conditions, solvent extraction and liquid-liquid partitioning 
 
Cultures of S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T were 
prepared using three different growth media: TSB, SHG and NL2 (see section 2.1.4). These 
three growth media were selected as they have very of different nutrient compositions. The 
three different growth media were used to test the effect of the growth medium on the 
production of NPs by the three actinobacteria, as discussed in the following section. On the 
final day of incubation, cultures were treated with XAD16 resin for 12 h, after which the cells 
and resin were harvested by centrifugation. XAD16 resin adsorbs organic molecules from the 
culture broth and releases the adsorbed compounds by treatment with organic solvent. The 
XAD16 resin and cell mass were extracted with MeOH and an organic extract was obtained 
(see section 2.2.3). The components of organic extracts were separated based on polarity by 
liquid-liquid partitioning with hexane, CHCl3, H2O and EtOAc (see section 2.5.1) as an initial 
purification. 
 
3.2.2 Bioassay, dereplication and purification 
 
Liquid-liquid partitions were screened for activity against a test panel that included the 
bacteria Escherichia coli WT (DSM-1116), E. coli tolC3 (DSM-26863), S. aureus ATCC-29213, P. 
aeruginosa DSM-24600, B. subtilis DSM-10T and M. smegmatis mc2155 (another 
mycobacterium used as a proxy for MTB),45 and the fungi C. albicans DSM-1665 and M. 
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hiemalis (see section 2.3.3). The results for this initial screening of semi-purified extracts 
provided a clear illustration of the effect of the growth medium on the production of NPs (see 
Table 3.1). S. speibonae PK-BlueT cultured using TSB showed weak activity against M. 
smegmatis mc2155 (EtOAc fraction, MIC50 = 160 μg/mL) while the SHG culture of the same 
bacterium exhibited no activity against M. smegmatis mc2155. Similarly, S. africanus CPJVR-
HT cultured using NL2 broth had strong activity against B. subtilis DSM-10T (CHCl3 fraction, 
MIC50 = 40 μg/mL) and S. pharetrae CZA14T cultured using SHG broth also showed strong 
activity against B. subtilis DSM-10T (EtOAc fraction, MIC50 = 5 μg/mL) while neither was active 
against B. subtilis DSM-10T in TSB cultures. Hence, it was demonstrated that the growth 
medium used in bacterial cultivation of these three South African actinobacteria affected the 
specificity and degree of biological activities. This variation in biological activity was due to 
differences in the nutrient composition of the growth media. Different media components 
can activate or repress different biochemical pathways, and therefore affect the production 
of bioactive NPs.53 The fractions with the strongest biological activities were selected for 
dereplication by HR LC-MS (see section 2.4.2).  
 
Table 3.1: Selected bioassay results for liquid-liquid partitioned fractions of S. speibonae PK-
BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T culture extracts. 
 S. speibonae PK-BlueT S. africanus CPJVR-HT S. pharetrae CZA14T 
Medium TSB TSB SHG SHG NL2 TSB SHG SHG TSB 
Partition CHCl3 EtOAc EtOAc EtOAc CHCl3 CHCl3 CHCl3 EtOAc EtOAc 
E. coli WT 
(DSM-1116) 
- - - - - - - - - 
M. hiemalis C B B - D B - - - 
S. aureus 
ATCC-29213 
- A - A C - - - - 
E. coli tolC3 
(DSM-26863) 
B C - - B - B B A 
B. subtilis 
DSM-10T 
C B D D E - G H - 
C. albicans 
DSM-1665 
- - A C A - - - - 
M. smegmatis 
mc2155 
- C - - B A - D - 
*MIC50 value key (μg/mL): A = 640; B = 320; C = 160; D = 80; E = 40; F = 20; G = 10; H = 5. 
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Active fractions were run on a HR LC-MS system and molecular formulae generated by the 
Chromeleon MS software were compared to molecular formulae found in the uninoculated 
broth media. Compounds that were present in the active fractions and absent from the 
uninoculated broth media were then compared to the Dictionary of Natural Products 
database.61 This was done to identify potentially novel NPs and to prioritise which fractions 
to select for further purification. Table 3.2 lists the molecular formulae obtained that are 
potentially novel, as they elicited no hits on the Dictionary of Natural Products database and 
did not match any compounds from the growth media.61 As time was limited, only the S. 
africanus CPJVR-HT NL2 culture CHCl3 extract, containing the suggested molecular formulae 
of C10H14O14, C10H12O13 and C12H8N6O2, and the S. pharetrae CZA14T SHG culture EtOAc 
extract, containing the suggested molecular formula of C11H16O3, were further purified by 
semi-preparative HPLC. The HPLC purification of the S. africanus CPJVR-HT NL2 culture CHCl3 
extract yielded 15 fractions, none of which exhibited biological activity when rescreened 
against the test panel. Hence, it was hypothesised that the activity previously observed for 
the CHCl3 extract was due to the combined effect of the compounds present in the crude 
mixture. The HPLC purification of the S. pharetrae CZA14T SHG culture EtOAc extract yielded 
14 fractions, only one fraction of which showed biological activity when rescreened against 
the test panel (against B. subtilis, MIC50 = 16 μg/mL). This active fraction was investigated by 
HR LC-MS and yielded an m/z = 1245.3178 (ESI+) and a suggested molecular formula of 
C58H52N8O24. This molecule is also potentially novel. Unfortunately, no fractions purified by 









Table 3.2: Suggested molecular formulae of potentially novel bioactive compounds from 





Suggested molecular formula 
S. speibonae PK-BlueT NL2 
CHCl3 C18H14N2O4 
EtOAc C11H6N6O3 










  EtOAc C58H52N8O24 
 
 
3.3 Biological activity against M. tuberculosis H37RvT 
 
All S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. pharetrae CZA14T crude extracts, semi-
purified extracts and purified compounds with activity against M. aurum A+ were also tested 
for activity against M. tuberculosis H37RvT using the protocol outlined in section 2.3.2. The 
crude EtOAc extract of ISP 2 growth medium cultures of S. speibonae PK-BlueT exhibited good 
activity against M. tuberculosis H37RvT with an MIC90 value of 2.0 μg/mL (see Table 3.3). 
Liquid-liquid partitioning of the S. speibonae PK-BlueT crude EtOAc extract yielded a CHCl3 
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fraction with an increased biological activity against M. tuberculosis H37RvT of 1.3 μg/mL. All 
compounds isolated from S. speibonae PK-BlueT extracts were obtained from CHCl3 fractions. 
 
Table 3.3: In vitro activity against M. tuberculosis H37RvT (MIC90) of crude extracts, semi-
purified extracts and pure compounds from S. speibonae PK-BlueT, S. africanus CPJVR-HT and 
S. pharetrae CZA14T ISP 2 cultures. 
Source Sample 
Activity against M. 
tuberculosis H37RvT (MIC90) 
(μg/mL) 
S. speibonae PK-BlueT 
Crude EtOAc extract 2.0 
CHCl3 fraction 1.3 
3.1 22.9 (135 μM) 
3.2 and 3.3 mixture 6.7 (26 μM) 
3.4 50 
S. africanus CPJVR-HT 
Crude EtOAc extract >50 
CHCl3 fraction 13.1 
S. pharetrae 
Crude EtOAc extract 13.0 
CHCl3 fraction 22.0 
  
 
The alkaloid 3.1 was moderately active against M. tuberculosis H37RvT with an MIC90 value of 
135 μM. This was not unexpected, as similar alkaloids have displayed good anti-TB activity.8 
A good example is isoniazid (1.1), which is also a pyridine alkaloid and one of the frontline TB 
chemotherapeutic drugs.8 Another pyridine alkaloid with good anti-TB activity against M. 




The mixture of 3.2 and 3.3 showed strong activity against M. tuberculosis H37RvT (26 μM). 
This strong activity was expected, as 3.2 is known to interfere with the hydroxyl group of 
lipopolysaccharides present in the cell wall of Gram negative bacteria.96 This disrupts the 
balance in the membrane lipid structure, damaging cytoplasm membrane flexibility, leading 
to cell swelling and lysis.96 Compound 3.3 is also known to possess highly selective antifungal 
properties with an MIC50 value of 5 μg/mL against C. albicans.97 However, 3.3 displayed 
negligible antibiotic activity against the Gram negative bacterial pathogens E. coli and P. 
aeruginosa.97 Unfortunately, no assumption can be made about which of 3.2 or 3.3 is 
responsible for the observed anti-TB activity, as this activity could be either one or a 
combination effect of the two. Compounds 3.2 and 3.3 should ideally be separated and tested 
individually for antimycobacterial activity.  
The isoflavone 3.4 showed weak activity against M. tuberculosis H37RvT (MIC90 = 195 μM). 
However, the oestrogenic potential of 3.4 in stimulating the growth of oestrogen-dependent 
breast cancer (MCF-7) has been investigated and was found to stimulate MCF-7 cell growth 
at concentrations of 0.001 μM in vitro and 50 μM in vivo in ovariectomised athymic mice.103 
This stimulation of MCF-7 cells by dietary 3.4 resulted in a slight, but significant, stimulation 
of tumour growth.103 Therefore, although 3.4 is produced naturally in the human gut through 
the metabolism of legumes by intestinal bacteria, the effect of high doses of 3.4 on human 
cancer cell lines requires investigation.99 This possible side-effect makes further research on 
3.4 as a potential anti-tubercular drug less attractive.  
Therefore, all the compounds isolated from S. speibonae PK-BlueT extracts displayed activity 
against M. tuberculosis H37RvT. However, these isolated compounds were all significantly less 
potent than the first-line drug, rifampicin (1.2). Rifampicin was used as a control in the M. 
tuberculosis H37RvT bioassay and yielded an MIC90 value of 0.043 μM. 
The crude EtOAc extract of ISP 2 growth medium cultures of S. africanus CPJVR-HT showed 
poor activity against M. tuberculosis H37RvT (MIC90 >50 μg/mL) while improved activity was 
observed in the CHCl3 fraction of this extract following liquid-liquid partitioning (MIC90 =13.1 
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μg/mL). A reason for the observed increase in bioactivity of the CHCl3 fraction is that the 
bioactive compound(s) is/are present in greater concentration(s) than in the parent fraction. 
Conversely, moderate activity against M. tuberculosis H37RvT was observed in the crude 
EtOAc extract of S. pharetrae CZA14T ISP 2 growth medium cultures (MIC90 = 13.0 μg/mL), with 
slightly poorer activity in the CHCl3 fraction (MIC90 = 22.0 μg/mL). This decrease in activity 
could be due to the separation of compounds that displayed bioactivity through a 
combination effect in the parent fraction.  
 
3.4 Conclusions and future work 
 
Three South African actinobacteria, S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. 
pharetrae CZA14T were found to produce compounds with antimycobacterial activity. Crude 
extracts and semi-purified extracts from cultures of all three bacteria showed activity against 
the MTB analogue M. aurum A+ and against M. tuberculosis H37RvT. In vitro bioassays for 
anti-TB activity against M. tuberculosis H37RvT for crude EtOAc extracts and semi-purified 
extracts of the three actinobacteria showed S. speibonae PK-BlueT to have the strongest 
activity. These bioassay results suggested that S. speibonae PK-BlueT is the most promising of 
the three actinobacteria for further anti-TB research.  
While the re-isolation of the antimycobacterial compound PK-B was not successful, it has 
been shown that S. speibonae PK-BlueT extracts contain other compounds with 
antimycobacterial activity. Compound 3.1, a 1:1 mixture of 3.2 and 3.3, and 3.4 all showed 
antimycobacterial activity against M. aurum A+ by bioautography, and therefore provide 
evidence that the bioassay-guided isolation of compounds from S. speibonae PK-BlueT 
extracts was successful. More promisingly, and supporting the strategy of screening against 
M. aurum A+ as an analogue of MTB, the compounds isolated – i.e., 3.1, a 1:1 mixture of 3.2 
and 3.3, and 3.4 – all showed activity against M. tuberculosis H37RvT with MIC90 values of 135 
μM, 26 μM and 195 μM, respectively. 
Streptomyces speibonae PK-BlueT was therefore successfully investigated in the context of NP 
anti-TB research. However, there were two main aspects of the isolation process that could 
be improved. The masses of crude extracts obtained from growth cultures were low and 
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crude extracts proved to be complex mixtures of compounds. This paucity of biomass 
hampered the isolation of novel NPs. Access to large-scale fermenters could potentially have 
resolved this issue, although there is also the possibility that the same compounds would not 
be produced by S. speibonae PK-BlueT under the conditions of larger-scale cultivation. This is 
certainly a possibility, as this study has shown that compound production by all three 
actinobacteria was dependent on the growth culture conditions. It was demonstrated that 
antimycobacterial activity of S. speibonae PK-BlueT extracts was dependent on culture 
volume, culture duration and growth medium, with best activity against M. aurum A+ 
observed in ISP 2 cultures with prolonged incubation times. MIC50 bioassay results against a 
panel of test organisms also established that the growth medium used in bacterial cultivation 
of all three actinobacteria did affect the degree and specificity of biological activity, although 
the cause of this phenomenon is unknown. Therefore, it could be worthwhile to experiment 
further with culture condition parameters – i.e., culture volume, culture duration and growth 
medium – in the cultivation of S. speibonae PK-BlueT, as this could prompt production of 
compound PK-B and allow the re-isolation of this compound. 
The second aspect of the implemented isolation process that could be improved is easy access 
to HR LC-MS. Monitoring of all stages of the isolation process by HR LC-MS would enable a 
more thorough dereplication of extracts. HR LC-MS, as a more sensitive technique than LR LC-
MS, could be used to more reliably identify known compounds and compounds originating 
from culture growth media. This information would save time and allow concentration of 
efforts to where they will be most constructive in achieving the aims of the research. This 
method of dereplication was successfully implemented during a research visit to HIPS and 
resulted in the identification of culture conditions and suggested molecular formulae of 
potentially novel, bioactive NPs from S. speibonae PK-BlueT, S. africanus CPJVR-HT and S. 
pharetrae CZA14T. In future, these compounds identified through HR LC-MS can be 
investigated further by re-isolation from upscaled growth cultures. Upscaling of these growth 
cultures could facilitate the isolation of pure, novel, bioactive compounds with sufficient 









Chapter 4: Experimental 
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4.1 Extraction and isolation of compounds from S. speibonae PK-BlueT cultures 
 
The South African actinomycete S. speibonae PK-BlueT was cultured using ISP 2 growth 
medium on a small scale (10 x 100 mL) and large scale (1 L in a single Erlenmeyer flask). Culture 
broths were extracted with EtOAc (3 x 30% of the culture volume) and extracts subjected to 
liquid-liquid partitioning and dereplication by LR LC-MS. Fractions with activity against M. 
aurum A+ by bioautography were further purified by benchtop column chromatography and 
HPLC and purified fractions rescreened against M. aurum A+. The structures of pure 
compounds with activity against M. aurum A+ were determined using LC-MS, NMR and GC-
MS analysis. 
A 14 d small-scale S. speibonae PK-BlueT culture yielded a bioactive liquid-liquid partitioned 
chloroform fraction. The bioactive compound N-phenylpyridin-2-aminium (3.1, 2.5 mg) was 
isolated by RP-HPLC (40 - 100% acetonitrile, 0.1% TFA in water) from this fraction.   
Six 14 d S. speibonae PK-BlueT cultures (small- and large-scale) yielded a bioactive liquid-liquid 
partitioned chloroform fraction. This fraction was semi-purified by RP-HPLC (40 - 100% 
acetonitrile, 0.1% TFA in water) and the 100% acetonitrile fractions combined and purified 
further by RP-HPLC (20 - 100% acetonitrile). A fraction with activity against M. aurum A+ by 
bioautography contained a 1:1 mixture of the fatty acids n-hexadecanoic acid (3.2) and 14-
methylpentadecanoic acid (3.3) (mixture total 2.2 mg). These carboxylic acids were 
derivatised to FAMEs for GC-MS analysis.   
Six 14 d S. speibonae PK-BlueT cultures (small- and large-scale) yielded a bioactive liquid-liquid 
partitioned chloroform fraction. This fraction was semi-purified by RP-HPLC (40 - 100% 
acetonitrile, 0.1% TFA in water) and the 40% acetonitrile fractions combined and purified 
further by benchtop column chromatography (isocratic 50% hexane/ethyl acetate and 
fractions rescreened for activity against M. aurum A+. The second of seven fractions obtained 
from benchtop column chromatography showed activity against M. aurum A+ was further 
purified by RP-HPLC (2 - 100% acetonitrile, 0.1% FA) to yield 7-hydroxy-3-(4-hydroxyphenyl)-




N-Phenylpyridin-2-aminium (3.1) : yellow oil; UV (MeOH) ε265 = 600.44, ε310 = 437.58; 1H NMR 
(MeOH-d4, 600 MHz) δ 7.99 (1H, dd, J = 7.9 Hz, H-4), 7.87 (1H, d, J = 6.1 Hz, H-6), 7.52 (2H, 
dd, J = 7.5 Hz, H-3’, H-5’), 7.39 (2H, d, J = 7.7 Hz, H-2’, H-6’), 7.37 (1H, m, H-4’), 7.17 (1H, d, J = 
9.1 Hz, H-3), 7.01 (1H, dd, J = 6.6 Hz, H-5); 13C NMR (MeOH-d4, 150 MHz) δ 153.8 (qc, C-2), 
145.4 (CH, C-4), 138.0 (CH, C-6), 137.0 (qc, C-1’), 131.5 (2 x CH, C-3’, C-5’), 128.5 (CH, C-4’), 
125.4 (2 x CH, C-2’, C-6’), 115.2 (CH, C-5), 114.8 (CH, C-3); HR-MS (ESI+) m/z 171.0918 (calcd 





N-Hexadecanoic acid (3.2)96 : yellow oil; 1H NMR (MeOH-d4, 600 MHz) δ 2.22 (2H, t, J = 7.6 
Hz, H2-2), 1.58 (2H, m, H2-3), 1.30 (2H, m, H2-4), 1.29 (2H, m, H2-15), 1.27 (20H, m, H2-5 – H2-
14), 0.86 (3H, m, H3-16); 13C NMR (MeOH-d4, 150 MHz) δ 177.7 (qc, C-1), 35.0 (CH2, C-2), 26.1 
(CH2, C-3), 30.2 – 31.1 (11 x CH2, C-4 – C-14), 23.6 (CH2, C-15), 14.4 (CH3, C-16); Hexadecanoic 
acid methyl ester: GC-EIMS: m/z (rel. int.) 270 [M+] (15), 239 (12), 227 (16), 143 (25), 83 (74), 





14-Methylpentadecanoic acid (3.3)97 : yellow oil; 1H NMR (MeOH-d4, 600 MHz) δ 2.22 (2H, t, 
J = 7.6 Hz, H2-2), 1.58 (2H, m, H2-3), 1.51 (1H, m, H-14), 1.30 (2H, m, H2-4), 1.29 (2H, m, H2-
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12),1.27 (14H, m, H2-5 – H2-11), 1.15 (2H, m, H2-13), 0.88 (6H, m, H3-15, H3-16); 13C NMR 
(MeOH-d4, 150 MHz) δ 177.7 (qc, C-1), 40.2 (CH2, C-13) 35.0 (CH2, C-2), 26.1 (CH2, C-3), 30.2 – 
31.1 (8 x CH2, C-4 – C-11), 30.2 (CH2, C-14), 28.5 (CH2, C-12), 23.0 (2 x CH3, C-15, C-16); 14-
Methylpentadecanoic acid methyl ester: GC-EIMS: m/z (rel. int.) 270 [M+] (15), 239 (12), 227 




7-Hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one (3.4)100 : white solid; 1H NMR (MeOH-d4, 
600 MHz) δ 8.05 (1H, s, H-2), 7.97 (1H, d, J = 9.0 Hz, H-5), 7.35 (2H, d, J = 8.9 Hz, H-2’, H-6’), 
6.83 (2H, d, J = 8.7 Hz, H-3’, H-5’), 6.83 (1H, d, J = 8.7 Hz, H-6), 6.69 (1H, d, J = 2.3 Hz, H-8); ); 
13C NMR (MeOH-d4, 150 MHz) δ 178.2 (qc, C-4), 169.7 (qc, C-7), 160.5 (qc, C-8a), 158.6 (qc, C-
4’), 154.2 (CH, C-2), 131.5 (2 x CH, C-2’, C-6’), 128.0 (CH, C-5), 125.6 (qc, C-1’), 124.7 (qc, C-3), 
118.8 (qc, C-4a), 118.7 (CH, C-6), 116.2 (2 x CH, C-3’, C-5’), 103.7 (CH, C-8); LR-MS (ESI+) m/z 
255.0 (calcd for C15H11O4 [M+], 255.0657). 
 
 




Aniline (0.44 mL, 4.8 mmol, 2 eq) was added to 2-bromopyridine (0.22 mL, 2.4 mmol) and 
refluxed at 170°C for 3 h with constant stirring and then cooled. The reaction mixture was 
dissolved in 1M NaOH (30 mL) and partitioned with ethyl acetate (3 x 30 mL). The ethyl 
acetate layer was washed with sat. NaHCO3 (30 mL) and brine (30 mL), dried over MgSO4 and 
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concentrated in vacuo to yield a grey powder.104 The crude grey powder was purified by 
benchtop column chromatography (gradient 2:1 hexane/dichloromethane to 100% 
dichloromethane) to yield N-phenylpyridin-2-amine (3.5, 67 mg) as a purple/grey solid.  
Compound 3.5 (20 mg) was dissolved in chloroform (10 mL), treated with 1M HCl (2 x 10 mL), 
shaken, partitioned with H2O (20 mL) and the aqueous layer concentrated in vacuo to yield 
3.1 (22 mg) as a yellow oil. No further purification was necessary. 
 
N-phenylpyridin-2-amine (3.5)94 : purple/grey solid; 1H NMR (CDCl3, 600 MHz) δ 8.05 (1H, d, 
J = 5 Hz, H-6), 7.51 (1H, dd, J = 7.9 Hz, H-4), 7.43 (2H, d, H-2’, H-6’), 7.26 (2H, dd, H-3’, H-5’), 
6.95 (1H, dd, H-4’), 6.82 (1H, d, J = 8.4 Hz, H-3), 6.7 (1H, dd, J = 6.2 Hz, H-5); 13C NMR (CDCl3, 
150 MHz) δ 157.8 (qc, C-2), 148.2 (CH, C-6), 142.5 (qc, C-1’), 138.9 (CH, C-4), 129.8 (2 x CH, C-
3’, C-5’), 122.9 (CH, C-4’), 120.7 (2 x CH, C-2’, C-6’), 115.5 (CH, C-5), 111.4 (CH, C-3); LR-MS 
(ESI+) m/z 171.1 (calcd for C11H11N2 [M+], 171.0922). 
 
N-phenylpyridin-2-aminium (3.1, synthesised)94 : yellow oil; 1H NMR (MeOH-d4, 600 MHz) δ 
8.05 (1H, dd, J = 8.2 Hz, H-4), 7.89 (1H, d, J = 6.2 Hz, H-6), 7.54 (2H, dd, J = 7.3 Hz, H-3’, H-5’), 
7.41 (1H, m, H-4’), 7.40 (2H, d, J = 8.1 Hz, H-2’, H-6’), 7.25 (1H, d, J = 9.2 Hz, H-3), 7.05 (1H, dd, 
J = 6.9 Hz, H-5); 13C NMR (MeOH-d4, 150 MHz) δ 153.3 (qc, C-2), 146.1 (CH, C-4), 137.1 (CH, C-
6), 136.4 (qc, C-1’), 131.6 (2 x CH, C-3’, C-5’), 129.0 (CH, C-4’), 125.8 (2 x CH, C-2’, C-6’), 115.3 
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Figure A1.1: HR-MS spectrum (ESI+) of 3.1. 
Figure A1.2: GC-MS spectrum (EI+) of 3.2. 
Figure A1.3: GC-MS spectrum (EI+) of 3.3. 






































Figure A2.1: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1. 
Figure A2.2: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for 3.1. 
Figure A2.3: COSY NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1. 
Figure A2.4: HSQC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1. 
Figure A2.5: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1. 
Figure A2.6: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for a mixture of 3.2 and 3.3. 
Figure A2.7: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for a mixture of 3.2 and 3.3. 
Figure A2.8: COSY NMR spectrum (MeOH-d4, 600 MHz) obtained for a mixture of 3.2 and 3.3. 
Figure A2.9: HSQC NMR spectrum (MeOH-d4, 600 MHz) obtained for a mixture of 3.2 and 3.3. 
Figure A2.10: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for a mixture of 3.2 and 
3.3. 
Figure A2.11: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.4. 
Figure A2.12: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for 3.4. 
Figure A2.13: COSY NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.4. 
Figure A2.14: HSQC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.4. 
Figure A2.15: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.4. 
Figure A2.16: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
Figure A2.17: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for 3.5. 
Figure A2.18: COSY NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
Figure A2.19: HSQC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
Figure A2.20: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
Figure A2.21: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1 (synthesised). 
Figure A2.22: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for 3.1 (synthesised). 
Figure A2.23: COSY NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1 (synthesised). 
Figure A2.24: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1 (synthesised). 
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Figure A2.2: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for 3.1. 
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Figure A2.7: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for a mixture of 3.2 and 3.3. 
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Figure A2.9: HSQC NMR spectrum (MeOH-d4, 600 MHz) obtained for a mixture of 3.2 and 3.3. 
 
























Figure A2.16: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
 
 
Figure A2.17: 13C NMR spectrum (MeOH-d4, 150 MHz) obtained for 3.5. 
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Figure A2.19: HSQC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
 
 
Figure A2.20: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.5. 
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Figure A2.21: 1H NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1 (synthesised). 
 




Figure A2.23: COSY NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1 (synthesised). 
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Figure A2.24: HMBC NMR spectrum (MeOH-d4, 600 MHz) obtained for 3.1 (synthesised). 
 
 
 
 
